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Undercapitalization is a major impediment for the growth and survival of Canadian life 
sciences firms.  Proficient management teams are the “sine qua non” criteria in the 
venture capital decision-making processes.  The purpose of this multicase study was to 
explore strategies successful venture capitalists use to improve their evaluation processes 
of life sciences management teams’ drug development capabilities.  The conceptual 
framework for this study was based on business process management.  The purposeful 
sample consisted of 10 venture capitalists located in the United States and Canada who 
had expertise evaluating life sciences management teams.  The data were triangulated 
from semistructured interviews, annual reports, company websites, and articles.  
Collected data were coded to identify underlying themes.  Several themes emerged from 
the analysis process: begin with the exit in mind, collapse learning timelines, conduct 
systematic due diligence, and cultivate and critique one’s drug development expertise.  
The findings may provide venture capitalists and other investors such as angel investors 
with a refined framework for improving investment decisions.  Life sciences management 
teams may also attract more private equity financing by understanding the vicissitudes of 
investor expectations.  Increased investment and venture capital support for life sciences 
companies may revitalize the development of new therapies and effect social change by 
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Section 1: Foundation of the Study  
Venture capitalists (VCs) invest in early-stage life sciences (LS) firms under 
conditions of information asymmetry.  The significant applied business problem is that 
uncertainty about the management team leads VCs to either refrain from investing or to 
make poor investment decisions.  One reason is that some VCs lack strategies to improve 
their evaluation processes of LS management teams’ drug development capabilities.  In 
this study, I seek to add to the literature and business practice on successful VC 
evaluation strategies of LS management teams.   
Background of the Problem  
Venture capital is a form of private equity investment where VCs commit 
financial resources to high-risk, early-stage companies that have the potential to develop 
into significant competitors in a market (Feld & Mendelson, 2014; Ramsinghani, 2014).  
VCs help develop their investee firms for several years until they can exit the investment 
via a merger and acquisition (M&A) or initial public offering (IPO; Feld & Mendelson, 
2014; Ramsinghani, 2014).  The overarching goal for VCs is to exit their investments 
profitably (Lehoux, Miller, & Daudelin, 2016) and to create value for their portfolio’s 
limited partners.  Further, a VC’s investment track record impacts his reputation and his 
ability to raise future funds.  Investments in LS companies with nascent drug 
technologies have the potential to simultaneously produce lucrative returns for venture 
capital portfolios and to address human health conditions.  Drug development is a 
complex, multifaceted, and expensive process, taking on average 10 to 15 years to 
complete (Bratic, Blok, & Gostola, 2014).  Regulatory approval by the United States 
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Food and Drug Administration (FDA) or the European Medicines Agency (EMA) 
represents the culmination of the drug development process and increases firm value 
(Lehoux, Miller, Daudelin, & Urbach, 2015).  VCs perceive that early-stage LS 
management teams lack the know-how for executing drug development while building 
their LS firm into a successful venture (Lehoux, et al., 2015; Moustakbal, 2014).  A 
paucity of venture capital investment in early-stage LS firms is a major impediment to 
their survival and growth (Fleming, 2015) and a barrier for developing new and 
innovative therapies.  My research objective was to identify what processes VCs use for 
evaluating LS management teams’ drug development capabilities.  
Problem Statement 
Scarce venture capital investment is a major impediment for the growth of 
Canadian LS firms (Fleming, 2015).  Although early-stage Canadian LS firms primarily 
favor venture capital financing (Veilleux, 2014), in 2016, the LS sector accounted for 
only 23% ($730 million) of overall venture capital investment in Canada (Canadian 
Venture Capital Association, 2017).  The general business problem is that the VCs 
deficient evaluation processes of management teams result in fewer investments and 
portfolio losses.  The specific business problem is that some VCs lack strategies to 
improve their evaluation processes of LS management teams’ drug development 
capabilities. 
Purpose Statement 
The purpose of this qualitative multicase study was to explore strategies 
successful VCs use to improve their evaluation processes of LS management teams’ drug 
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development capabilities.  The target population included American and Canadian 
venture capital firm partners who successfully improved their evaluation processes of at 
least one LS management teams’ drug development capabilities in the past 10 years.  The 
implications for positive social change included improving investment decisions and 
stakeholder returns, which can enhance investments in LS firms, ultimately enabling 
development of innovative therapies to treat illnesses in areas of unmet medical needs to 
improve patient lives.  
Nature of the Study 
The problem statement, purpose statement, and research question(s) determine the 
ideal method of scientific inquiry for a problem (Burton, 2014).  I reviewed qualitative, 
quantitative, and mixed methods approaches.  Sarma (2015) highlighted the 
misunderstood paradigmatic differences between qualitative and quantitative research.  A 
fundamentally postpositivist perspective, the quantitative approach employs deductive 
reasoning and hypothesis generation to determine the relationship between independent 
and dependent variables (Barnham, 2015).  Conversely, in qualitative studies, scholars 
employ inductive, constructivist reasoning, while preserving robust scientific standards 
(Morse, 2015).  Since using inductive approaches generates novel insights that are 
challenging to measure quantitatively, the explorative nature of my inquiry, namely, VC 
evaluation of LS senior executives, the qualitative method is appropriate for my study.  
Finally, while some researchers use the mixed method, which is a combination of 
qualitative and quantitative data collection (Alavi & Habek, 2016), the additional time 
and complexity make it unsuitable for my study.  
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After determining that a qualitative approach was most appropriate, I looked at 
five designs commonly used in qualitative research: phenomenology, grounded theory, 
narrative, ethnography, and case study (Lewis, 2015).  The phenomenological approach 
involves interviews to describe the lived experiences of individuals about a phenomenon 
(Lewis, 2015).  Phenomenology was not optimal because my research question involves 
analyzing VCs actions and not the personal meanings of events or phenomena they 
experienced.  Grounded theory is suitable for researchers seeking to generate theory from 
a phenomenon (Cho & Lee, 2014).  I rejected a grounded theory design because the 
purpose of a doctoral study is to address a business problem and not to generate theory. 
Narrative design and ethnographic design were not fitting to address how VCs evaluate 
LS executives.  Using the narrative design enables researchers to identify and explore the 
meanings of participants’ life stories (Fletcher, De Massis, & Nordqvist, 2015) and using 
an ethnographic design requires studying groups’ cultural behavior through 
predominately observation (Segelström & Holmlid, 2015). Case study researchers 
conduct an in-depth analysis of a case bound by time and activity (Ketoviki & Choi, 
2014). Therefore, the use of a multicase study design was appropriate to explore the 
decision-making processes VCs used for actual LS investments. 
Research Question  
What strategies do successful VCs use to improve their evaluation processes of 
LS management teams’ drug development capabilities? 
Interview Questions  
The following questions guided the interview process.  
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1.  How do you determine a LS management teams’ capability for developing a 
drug through to commercialization (e.g., discovery, pre-clinical, clinical research, and 
post marketing)? 
2.  Please describe the process your organization uses to assess the drug 
development capabilities of a LS management team. 
3.  What were the key challenges to implementing the process of assessing LS 
management teams? 
4.  How did you address the key challenges to implementing the process for 
assessing LS management teams? 
5.  How does your organization assess the effectiveness of your process for 
evaluating LS management teams? 
6.  How, if at all, has your organization improved the effectiveness of your 
process for evaluating LS management teams? 
7.  What other information would you like to share about evaluating LS 
management teams’ capabilities that I did not ask?  
Conceptual Framework 
A conceptual framework is a deliberately constructed means for exploring and 
interpreting phenomena in a research study (Green, 2014).  Business process 
management (BPM) is the conceptual framework for this study.  BPM is an iterative 
method developed to assist organizations to continually manage and improve their key 
business processes (Koryl & Mazur, 2017).  In 1911, Frederick Winslow Taylor 
pioneered the scientific study of work and standardization of processes, and BPM 
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continued to evolve in the information era with improving efficiency, workflows, and 
processes (Margherita, 2014).  Specific BPM processes include (a) discovery, (b) 
analysis, (c) redesign, (d) implementation, and (e) controlling (Mendling, Baesens, 
Bernstein, & Fellmann, 2017).  BPM provided me with a foundation to investigate, 
analyze, and interpret the evaluation processes VCs use to determine management teams’ 
drug development capabilities.  
Operational Definitions 
Due diligence:  Due diligence is the process where a VC comprehensively 
researches aspects of a prospective investee company prior to making an investment 
decision (Blum, 2015). 
Early-stage company:  Early-stage companies follow the seed stage and are an 
innovative stage of a firm’s development focused on product and business development 
(Lahr & Mina, 2014). 
Life sciences industry:  Life sciences industry is an umbrella term including 
research, development and manufacturing in diagnostics, biopharmaceuticals, 
pharmaceuticals, and medical devices for human health (Government of Canada, 2017). 
Limited partnership vehicle:  A limited partnership vehicle is the fund VCs raise 
from limited partners (e.g., government, pension funds, and large corporations) for 
investing in new ventures (Kollmann, Kuckertz, & Middelberg, 2014). 
Venture capital:  Venture capital is a high-risk private investment during the seed, 
early-stage, or late-stages high technology or life sciences companies made in exchange 
for equity, governance, and control (dos Santos Dias & Alvaroda Silva Macedo, 2016). 
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Assumptions, Limitations, and Delimitations 
Assumptions 
Assumptions in scholarly research are underlying thoughts and beliefs about the 
topic that are not overtly articulated (Gardner & Johnson, 2015).  I made several 
assumptions during this doctoral study.  First, VCs wish to increase investment in LS 
firms.  Second, BPM is a suitable framework to investigate, analyze, and interpret VC 
evaluation processes for LS executives.  Third, some VCs lack strategies to evaluate LS 
senior management capabilities.  Fourth, participants will comprehensively and honestly 
respond to the interview questions.  Fifth, interviewing VCs will satisfactorily answer the 
research question. 
Limitations 
Studies have limitations because the researcher cannot control all aspects 
affecting the study (O’Brien, Harris, Beckman, Reed, & Cook, 2014).  First, I relied on 
VCs to accurately recall LS investments they assessed in the past 10 years.  Second, VC 
interview responses may have been affected by their geographic location, thereby 
limiting the generalizability of results.  Third, VCs had different levels of experience with 
LS investing. 
Delimitations 
A researcher defines the study boundaries that may influence study results 
(O’Brien et al., 2014).  First, I limited this study to VC evaluation of senior management 
drug development capabilities and not to other pertinent factors in VC investment 
criteria, such as LS firm assets, competitors, the economy, or firm valuation.  Second, my 
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intent was to conduct the interviews with VC partners or managing directors and not VC 
analysts or associates.  Third, I only interviewed VC’s based in Canada and the United 
States and solely consider business process management as the conceptual framework. 
Significance of the Study 
A VC who invested in a LS company must have been confident in the capabilities 
of the management team. The LS management team demonstrated characteristics 
amenable to leading and commercializing a drug. Understanding and modeling the 
strategies VCs used to evaluate executives may help increase investments in LS firms.  
Contribution to Business Practice  
The results from the study may contribute to effective business practice and 
solutions regarding venture capital investment strategies in LS firms.  The LS sector is an 
important contributor to the Canadian economy.  In 2014, the sector contributed $117 
billion to the gross domestic product (GDP) and constituted 41%, 24%, 12%, and 13% of 
Ontario, Quebec, British Columbia, and Alberta’s GDP, respectively 
(PricewaterhouseCoopers, 2015).  Despite the contributions to the economy, early-stage 
Canadian LS companies have encountered difficulties developing and commercializing 
their products due to lack of investment capital (Government of Canada, 2014).  
Furthermore, the Government of Canada (2014) warned the problematic LS market 
dynamics in Canada may result in increasing attrition rates and relocation to other 
markets, such as the United States or Europe. 
Venture capital support could be instrumental for the LS challenges in Canada. 
Along with capital funding, experienced VC’s support management teams with business 
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coaching and wider networks, which can lead to signaling a firms’ quality to the broader 
investment community (Colombo, Cumming, Mohammadi, Rossi-Lamastra, & Wadhwa, 
2016).  Formalization and elucidation of the process may lead to more interest in LS 
research and development (R&D) and investment.  Additionally, findings from this study 
may be valuable to nascent LS organizations whose leaders are seeking to raise venture 
capital funds for their companies. 
Implications for Social Change  
The implications for positive social change are manifold.  As the world 
population is expected to increase to nearly 10 billion by 2050 (United Nations, 2017) 
and chronic disease prevalence is expected to rise by 57% by the year 2020 (World 
Health Organization, 2016), innovative new treatments are needed.  Health care 
innovation saves and improves lives (Pitts, 2015) and LS firms are instrumental in 
delivering pioneering R&D.  The results of this study may lead to new investments in LS 
firms, enhanced growth and new employment for the sector.  New investments may also 
lead to treatments for diseases, sustainable food sources, and clean energy innovation.  
Additionally, LS firms may help address the significant unmet needs in rare diseases 
research.  
Rare diseases are devastating for patients, frustrating for health care providers, 
and a growing concern for health insurance companies.  The National Institutes of Health 
(2016) estimated that out of the approximately 7,000 rare diseases affecting 25 million 
Americans, only a few hundred have available treatments.  Notably, since the passage of 
the Orphan Drug Act of 1983 by the FDA, treatments became available to treat rare and 
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undertreated diseases (Herder, 2017).  VCs can help identify and invest in LS firms with 
rare disease drug development.  Consequently, a better understanding of VC evaluation 
processes may eventually lead to new and efficacious treatments for addressing rare 
diseases.  
A Review of the Professional and Academic Literature 
The purpose of this literature review is to summarize, compare, and contrast 
sources related to strategies for VCs to improve their evaluation processes of LS 
management teams’ drug development capabilities.  BPM served as a framework for how 
VCs can improve their evaluation processes.  I divided the literature review into three 
categories: (a) business process management, (b) venture capital, and (c) life sciences.  I 
selected peer-reviewed articles from Business Source Complete, Academic Source 
Complete, Google Scholar, ProQuest Central, ABI/Inform, Science Direct, and Emerald 
Management Journal.  Keywords for the searches included venture capital, venture 
capital investment process, venture capital decision-making process, venture capital 
fundraising, venture capital exits, life sciences, drug development, and business process 
management.  
Additionally, I collected information from world health organizations, 
government health websites, and venture capital associations.  I developed the literature 
review using 92% peer-reviewed journals (210 articles) and 95% sources published 
within 5 years of 2018.  In total, I cited 229 sources in the literature review, representing 





Frequency of the Study Sources 








202 8 210 
Books 6 3 9 
 
Websites 0 1 1 
 
Business Process Management  
The conceptual framework for this study is BPM.  BPM emerged during the 20th 
century.  Jeston and Nelis (2014) credited BPM’s origins to Taylor Frederick, who 
explored methods to improve industrial processes and reduce waste in the early 1900s.  
Hammer (2015) illustrated BPM as business process improvement life cycles presented 
by Shewart, Deming, and Juran, who advocated using performance metrics and 
consistency measures for continuous quality improvement, such as the plan-do-check-act 
cycle.  Later, Hammer introduced business process reengineering in 1990, distinguishing 
it as designing processes to achieve business objectives and to abandon nonyielding 
processes.  Processes misaligned with corporate aims contribute to inefficiencies and 
financial losses (Hammer, 2015). 
BPM is a management discipline about deliberately, collaboratively, and 
systematically improving business processes to accomplish organizational objectives 
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(Hammer, 2015; Jeston & Nelis, 2015).  Continuous business process improvement 
differentiates BPM from one off business process improvement initiatives as seen in Six 
Sigma, Lean, and Total Quality Management (Hammer, 2015; Jeston & Nelis, 2014).  
BPM requires the ability to apply 360-degree, outside-in perspective for business process 
improvement (Kohlborn, Mueller, Poeppelbuss, & Roeglinger, 2014; Müller, Schmiedel, 
Gorbacheva, & vom Brocke, 2016).  Hammer (2015) illustrated that a customer-centric 
approach includes customers, results, and outputs in an interdependent triad.  Customers 
and stakeholders demand results and results are a function of its processes.  Likewise, 
portfolio fund investors value high returns and high returns depend on continuous 
improvement of investment processes.  
Continuous, iterative improvement underpins BPM.  Berman (2014) articulated 
that processes are the group of activities that convert resources, such as time or a 
commodity, into a quantifiable output or result.  Hammer (2015) offered that in BPM, 
processes include end-to-end workflows across the organization which creates customer 
value.  Further, Hammer (2015) argued that consistently executed processes and their 
subsequent outputs are not beneficial if they do not contribute towards organizational 
goals.  Panagacos (2012) highlighted that dissecting an organization’s processes helps 
illustrate gaps and opportunities towards achieving strategic objectives.  Designing 
complex business processes requires extensive domain knowledge and intimate 
knowledge of the company’s operations and strategic direction (Deng et al., 2017; 
Loarne-Lemaire & Maalaoui, 2015).  The VCs overarching objective is to ensure every 
investment is profitable for their portfolio’s limited partners.  The living-dead 
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(Ramsinghani, 2014) or written-off investments because of flawed investment practices 
extract value from portfolio investors.  Extensive domain knowledge about their 
prospective investments, such as in drug development, will help decrease uncertainty in 
VC investments.  The interplay between the venture capital firm’s objectives, the 
portfolio objectives, and the drug development process affect the VCs evaluation process 
of LS management teams.  
Business process management life cycle.  In BPM, all processes must align with 
the organization’s strategic goals.  BPMlife cycle includes continuous improvements.  
The BPM life cycle begins with the design and modeling phase.  The process design and 
modeling stage involves identifying, analyzing, and conceptualizing current and future 
processes (Mendling et al., 2017; Rosemann & Brocke, 2015).  Organizations aiming for 
process improvement must scrutinize every step in the process (Nadarajah & Syed Kadir, 
2016).  Brocke et al. (2014) argued that simple processes are often best.  Further, 
management must consider the financial implications of process changes (Bolsinger, 
2015; Borch & Batalden, 2015).  Trkman, Mertens, Viaene, and Gemmel (2015) posited 
that any process redesign must begin with customer requirements.  Process modeling is 
for reconfiguring, scrutinizing workflows and inefficiencies, often in visual form (Jeston 
& Nelis, 2014; Lahajnar & Rožanec, 2016).  The remodeled and redesigned process must 
align with business strategy (Sikdar & Payyazhi, 2014).  
The remaining phases of the BPM lifecycle are execution, control, and 
optimization.  During process execution, the redesigned process users are first trained on 
the new procedures, including the adoption of any new technologies (Mendling et al., 
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2017).  Posttraining, end users perform the new processes (Rosemann & Brocke, 2015).  
Process control is a monitoring stage to ensure that the process is followed according to 
design (Mendling et al., 2017).  This stage also encompasses measuring process 
outcomes according to plans (Mendling et al., 2017).  Data analysis may include risk 
assessment, identifying inefficiencies, and other performance indicators, such as budgets 
and resource allocation (Rosemann & Brocke, 2015).  Finally, in process optimization, 
deficiencies or errors identified during data analysis are addressed (Rosemann & Brocke, 
2015).  Procedures or sequences that were not practical or unyielding during the 
execution phase are reevaluated and redesigned (Mendling et al., 2017).  Optimization is 
essential for continuous improvement, a core feature in BPM. 
Hammer (2015) argued that most business situations are not unique and can adopt 
generic processes.  Instead of mimicking others’ processes, Brocke, Zelt, and Schmeidel 
(2016) suggested that managers should customize BPM initiatives depending on the 
business environment, culture, and objectives.  Ignoring the unique context of any 
process and forcing a standardized approach may lead to additional problems (Brocke et 
al., 2014).  Contingency theory is a complementary mindset.  Contingency theorists 
posited that the best decision is unique to the situation, environment, and decision makers 
(Tarter & Hoy, 1998).  Further, when a decision includes information asymmetry, the 
decision makers should consider a flexible, trial and error based strategy contingent upon 
the situation (Tarter & Hoy, 1998).  VCs applying BPM to their investment processes 




The research question is what strategies successful VC partners used to evaluate 
LS management teams’ drug development capabilities to increase investments and 
minimize portfolio losses.  Minimizing portfolio losses requires selecting the right 
investments and evaluating management teams under conditions of uncertainty and 
information asymmetry.  Every VC has a process to follow when vetting a LS 
management team, which can be a standard evaluation process or a unique process 
contingent upon the situation.  From a BPM perspective, the VCs should consider their 
portfolio objectives when evaluating LS management teams.  Based on the declining 
venture capital investment in Canadian early-stage LS firms, VCs have reason to analyze, 
redesign, remodel, and continuously improve their end-to-end investment decision 
making processes.  
Applications of business process management.  Researchers have not 
previously applied the BPM framework to venture capital evaluation of entrepreneurs or 
the venture capital investment process.  Information technology (IT) applications for 
BPM dominate the extant literature.  Several researchers interpreted BPM predominately 
as a technology platform (Del Giudice, 2016; Krumeich, Weis, Werth, & Loos, 2014) 
Pourmirza, Peters, Dijkman, and Grefen (2017)  suggested that BPM techniques will be 
imperative for user adoption and acceptance for the Internet of Things applications.   
Others claimed that process management professionals and IT professionals are the most 
important actors in BPM initiatives (Paiano, Caione, Guido, Martella, & Pandurino, 
2015; Rahimi, Møller, & Hvam, 2016). Wong, Tseng, and Tan, (2014) suggested that 
stronger managerial BPM capabilities were associated with enhanced organizational 
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technical BPM applications.  Krstić, Kahrović, and Stanišića (2015) reported that BPM 
improved Serbian hotel operations such as increasing efficiencies in housekeeping, guest 
arrivals and departures, and food services.  In a study of Czech manufacturing companies, 
Tucek (2017) found that problems arising from significant inefficiencies were the 
primary precursors for process change.  Son and Kim (2014) asserted that BPM systems 
improved a Korean ship hull production design.  Pradabwong, Braziotis, Tannock, and 
Pawar (2017) reported that manufacturing firms which adopted BPM improved their 
firms’ performance and supply chains.   
BPM applications to improve process efficiencies and improve company 
profitability are chronicled predominately in service, manufacturing, and operations 
establishments.  The BPM approach is about improving end-to-end business processes to 
accomplish organizational goals.  Venture capital investment evaluations are a process 
which warrants scholarly inquiry in a BPM context: continuous process improvement and 
refinement to meet its portfolio objectives.  
Business process management and the theory of constraints.  A supporting 
theory to BPM is the theory of constraints. The theory of constraints is based on the idea 
that a process constraint hinders maximum performance, and that recognizing and 
improving these constraints can increase effectiveness (Izamailov, 2014).  Pretorius 
(2014) suggested users should not discard system constraints but rather should maximize 
them as much as possible.  For example, if the major element lacking in an investment 
proposal is the management team, VCs could consider how they can help improve the 
management teams’ drug development capabilities instead of rejecting the deal.  Cox 
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Robinson, and Maxwell (2014) applied the theory of constraints to a fledgling family 
medicine practice.  In the improved medical practice, physicians focused on patient care 
with minimal interruptions from support staff, leading to better and more efficient care 
(Cox et al., 2014).  Huang, Chen, Chiu, and Chen (2014) applied the theory of constraints 
by reallocating a manufacturing company’s limited resources towards the main 
operations bottleneck to improve process effectiveness.  Based on Huang et al.’s findings, 
VCs could redirect more resources on evaluating management teams during deal 
screening. 
VCs allocate significant time to screening deals (Nanda, Samila, & Sorenson, 
2017).  The theory of constraints could provide an alternative conceptual framework for 
describing how VCs can improve their evaluation processes of LS management teams.  
The theory of constraints would include assessing the constraints (e.g., specific 
management team capabilities) in the context of the entire investment decision making 
process.  VCs who identify the management team characteristics that are a major 
constraint, when considered in combination with other investment criteria, can help 
improve the investment process and create value for the portfolio. 
 Alternative theories.  Investment theories and behavioral theories could provide 
alternative perspectives for investigating strategies VCs use to improve their evaluation 
processes of management teams.  I considered applying two investment theories, the 
modern portfolio theory (MPT) and the capital asset pricing model, to address the 
research question.  MPT is based on the premise that investors could construct an 
efficient frontier of diversified investments to maximize returns based on a certain level 
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of risk (Loviscek, 2015).  Biswas (2015) explained that diversifying a portfolio to include 
investments in different industries and different sized companies will decrease overall 
risks and improve portfolio returns.  MPT has been applied in many different industries.  
Aerts, Botzen, and Werners (2015) leveraged MPT principles to reduce risks in water 
management by diversifying flood management investments.  Leingang (2017) applied 
MPT to weigh different criteria in personnel selection, thereby mitigating risks and 
uncertainty in hiring decisions.  In the nonprofit sector, Grasse, Whaley, and Ihrke (2015) 
articulated that although non-profits could pursue more than one revenue stream to 
reduce dependency on one income source, a diversification strategy could be inefficient 
under conditions of limited resources.   
The capital asset pricing model (CAPM) builds on the diversification strategy 
proposed in MPT.  In the CAPM, investors measure the required rate of return of 
individual investments in relation to the other investments in the portfolio and not in 
isolation (Elbannan, 2015).  Dai and Lan (2014) applied the CAPM by selecting a 
portfolio with diverse betas in technology, manufacturing, real estate, and miscellaneous 
industries to reduce the investment risk of a single stock.  Kuehn, Simutin, and Wang 
(2016) applied the CAPM for valuing companies based on their capacity to fill 
employment vacancies.  Companies who filled their employment vacancies faster 
reported higher equity returns (Kuehn et al., 2016).  Other scholars applied the CAPM to 
value forestry assets (Yao & Mei, 2015) and gold exchange traded funds (Aravind, 2015). 
Applying MPT and the CAPM principles to the present study, VCs would 
evaluate the management team of one prospective LS investment in relation to other 
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management teams in the portfolio.  Specifically, VCs would evaluate LS management 
teams’ drug development capabilities based on how different or similar they are to other 
LS management teams’ drug development capabilities in the portfolio.  The VC’s 
evaluation of management teams would be relational to other portfolio members instead 
of as individual investments.    
Another theory to explore VC strategies in evaluating management teams is social 
judgement theory.  Social judgement theorists suggest people make evaluations about a 
situation based on their past experiences, and that people are anchored to their pre-
existing judgements (Behrens, 2016).  Using a social judgement theoretical framework, 
Behrens (2016) demonstrated that managers’ actual decision-making processes differed 
from their self-reported decision-making processes.  Gonzalez-Vallejo and Lavins (2015) 
applied the social judgment theory to measure the accuracy of consumers’ judgements of 
nutrition facts relative to a gold standard.  Akhul and Gupta (2014) contended that 
recruiters focused on different cues to evaluate one job candidate, which led to different 
hiring recommendations.  Based on social judgement theory, VCs who evaluate 
management teams and make investment decisions will have different anchors, different 
investment histories, and different worldviews about a management teams’ drug 
development capabilities.  Consequently, the social judgement theory could illuminate 
why some VCs have successful evaluation processes.  Overall, despite the availability of 




Venture Capital  
Venture capital is a subasset class of private equity and traditional alternative 
investments (Morrisette & Hines, 2015; Ramsinghani, 2014).  Following World War II, 
the first venture capital firm, the American Research and Development Corporation 
(ARDC), invested $30 million USD in 87 nascent technology companies from 1946-1966 
(Rotch, 1968) in exchange for equity (Feld & Mendelson, 2016; Gompers & Lerner, 
2001).  VCs purchase substantial equity stakes in seed, early and late stage companies for 
a period of 5 to 10 years (Ramsinghani, 2014; Rotch, 1968) with high risk, high 
information asymmetry (Gompers & Lerner, 2001), and expectations of substantial gains 
(Kryzanowski & Giraldeau, 1977).  Because of the equity holding mechanism, venture 
capital investments are highly illiquid.  Importantly, investments with a longer time to 
maturity necessitate larger capital gains per year, that is, 150% to 200% above cost 
(Rotch, 1968).  Consequently, expediting the time to exit is critical for venture capital 
success.  
Types of venture capital firms.  The types of professionally managed venture 
capital firms are heterogeneous, namely, independent venture capital (IVC), government- 
owned venture capital (GVC), or corporation-owned venture capital (CVC).  Although 
more than one venture capital firm can invest in a portfolio company, Colombo and 
Murtinu (2017) discovered that more than one type of venture capital investment in a 
company does not necessarily lead to better firm outcomes.  Bertoni and Tykvová (2015) 
reported that while GVC does not independently increase innovation in firms, GVC 
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investments complement IVC investments.  The differing overarching goals for IVC, 
CVC, and GVC may explain Colombo et al.’s and Bertoni et al.’s varying findings.  
Some large corporations house a venture capital division to make investments in 
nascent start-up companies.  Chemmanur, Loutskina and Tian (2014) argued that CVCs 
and IVCs objectives are fundamentally divergent.  One parent corporation typically funds 
the CVC, as opposed to several limited partners funding the IVC (Souitaris & Zerbinati, 
2014).  Organizations such as Google and Microsoft leverage their CVC programs to 
advance their R&D programs, build new capabilities, and enhance their market 
competitiveness (Da Gbadji, Gailly, & Schwienbacher, 2015).  CVC firms particularly 
concentrate on innovation-creation and strategic alliance objectives that exploit synergies 
(Asel, Park, & Velamuri, 2015), even if it causes them to retain their investments for 
longer than 10 years (Guo, Lou, & Pérez-Castrillo, 2015).  Conversely, the IVC firms’ 
predominant objective is a rapid and profitable exit (Galloway, Miller, Sahaym, & 
Arthurs, 2017). 
Publicly funded investments, namely government-managed venture capital (GVC) 
can support new businesses.  Bertoni, Colombo, and Quas (2015) discovered that GVCs 
invested in seed or early stage companies when other VCs refrained from investing GVC 
supports start-up and early-stage firms similar to IVC and CVC in regions such Europe, 
Canada, Australia, and the UK (Guerini & Quas, 2016).  Government venture capital 
backed firms in Europe are better positioned to receive IVC in subsequent funding founds 
(Guerini & Quas, 2016).  Contrarily, emerging countries show an inverse relationship 
between GVC and IVC funding for firms (Herrera-Echeverri, Haar, & Estevez-Bretón 
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(2014), indicating fewer opportunities for private equity investors when government 
intervenes.  Colombo, Cumming, and Vismara (2016) concurred, suggesting that while 
GVC (e.g., Canadian Venture Capital Action Plan) helps close the financing gap for 
nascent firms, public funding may discourage private investments.  
Despite belonging to venture capital enterprises, CVC, GVC, and IVC have 
different investment objectives.  Consequently, their investment processes and LS 
management evaluation processes do not align.  A CVC firm may value a prospective LS 
management team’s collaboration and partnership potential over their drug development 
capabilities.  Similarly, government policies for stimulating the economy influence GVC 
investment objectives.  For example, early-stage firms could have more luck soliciting 
GVCs during economic downturns. Moreover, GVCs may not emphasize the 
management evaluation process.  Finally, because the IVC firm’s main aim is a profitable 
investment exit and value creation for the portfolio, VCs working in IVC firms can apply 
a BPM approach to improve processes, such as scrutinizing the LS management teams’ 
drug development capabilities.  VCs employed in IVC firms can continuously improve 
their evaluation processes of LS management teams by analyzing, redesigning, and 
optimizing their investment processes to create value for the portfolio.  
Venture Capital Funds 
Venture capital fundraising in IVC firms is delineated as follows.  First, VCs 
(e.g., managing directors or general partners) raise one or more closed ended limited 
partnership funds (entities) from limited partners such as pension funds, corporations, 
funds of funds, high net worth investors (Feld & Mendelson, 2016; Ramsinghani, 2014), 
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and endowments (Bermiss, Hallen, McDonald, & Pahnke, 2017).  Second, the VCs invest 
the funds into several portfolio companies over 2 to 5 years (Feld & Mendelson, 2016; 
Ramsinghani, 2014) in a series of stages or rounds (Bhagat, 2014).  Third, after holding 
the investments for up to 10 years, VCs harvest the investment via an exit opportunity, 
and calculate the internal rate of return, which is a function of the capital invested and the 
holding period (Bhagat, 2014).  A longer holding period requires higher returns to 
account for risk and the time value of money. The venture capital firm charges a 
management fee (approximately 15% of committed capital) and a percentage (e.g., 20 to 
30%) of the profits per fund (Ramsinghani, 2014).  The combined investments constitute 
the portfolio. In short, VCs are stewards of the resources entrusted to them by portfolio 
investors. 
Venture Capital Exits 
A vital consideration for VCs is determining the likelihood of profitably exiting 
an investment and minimizing chances of investment abandonment or write-offs (Arcot, 
2014).  VCs capitalize on their portfolio firm investments through an IPO equity sale or 
by making a trade sale to a buyer via M&A (Ragozzino & Blevins, 2016; Teker, Teker, 
& Teraman, 2016).  Cannice, Allen, and Tarrazo (2016) conducted a Delphi study with 
Silicon Valley VCs to report that the dynamic venture capital environment necessitates 
more scholarly research on exit strategies.  VCs create value for portfolio investors when 
they exceed investment return expectations.  The probability of profitable LS investment 
exits may increase when VCs apply BPM principles.  VCs can continuously improve 
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their processes to achieve the end-to-end portfolio objective, namely, high investment 
returns. 
Initial public offering.  An IPO is a process for publicly issuing a private 
company’s shares (Graham, 2006).  Key intermediaries in the IPO process include the 
firm’s management, investment banks, underwriters, VCs, and analysts (Lowry, 
Michaely, & Volkova, 2017).  For the founder, an IPO represents selling partial 
ownership of a company to investors in exchange for capital.  For intermediaries, 
individual investors and institutional investors, an IPO represents an opportunity to 
capitalize on a promising company (Anderson & Zastawniak, 2017).  An oversupply of 
new IPO listings results in corrections in subsequent years (Satta, Notteboom, Parola, & 
Persico, 2017), implying IPO listing volumes is cyclical in nature, with corresponding 
peaks and valleys.  
A successful IPO represents an important milestone for a portfolio firm and the 
VC.  Ragozzino and Blevins (2016) advised that shorter venture capital investment 
duration in a portfolio firm leads to a higher probability of exit via IPO.  The portfolio 
firm allocates the additional capital towards advancing R&D, attracting new talent, 
expanding operations, and promoting the firm’s image and profile (Kumar, 2017).  
Notably, the portfolio firm did not consider debt reduction and interest payments as 
important reasons for a public equity offering (Meluzin & Zinecker, 2014).  From the 
VC’s vantage point, an IPO improves liquidity and is the most lucrative departure route 
post lock-up period, which is a restricted trading period (Pennachio, 2014).  
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In the United States, Megginson, Meles, Sampagnaro, and Verdoliva (2016) 
reported that VCs tangible and intangible resources led to higher post-IPO stability for 
VC-backed firms.  Similarly, VC-backed Indian portfolio firms reported higher 
compound annual growth rates post-IPO (Raghupathy & Thillairajan, 2015).  Liao, Lu, 
and Wang (2014) reported Taiwanese portfolio firms were more financially stable for an 
average of 7 years post-IPO.  Taken together, the evidence from several countries 
suggests the VCs capital, screening, monitoring, and coaching value-add contributes to 
the superior post-IPO performance of their portfolio firms.  
Foreign VC-backing.  VCs are not limited to investing in their country of origin 
and are often successful in foreign markets.  Based on an international IPO analysis, 
Cumming, Knill, and Syvrud (2016) conveyed that foreign VCs had more IPOs and 
relatively more lucrative exits.  Hearn, Oxelheim, and Randøy (2016) added that foreign 
VCs in Africa continued to foster and coach their portfolio firms for a significant time 
post-IPO, leading to enhanced long-term performance.  Foreign VCs were also more 
likely to pursue IPOs on foreign stock exchanges versus local VCs (Cheng & 
Schwienbacher, 2016).  Kong, Nitani, and Riding (2016) concluded that foreign VC IPOs 
in Canada were faster, more lucrative, and occurred more frequently than local VCs.  
Faster time-to-IPO may have important implications for the portfolio firm.   
Grandstanding.  Grandstanding is a significant feature in VC-backed IPOs.  The 
grandstanding phenomena in venture capital, proposed by Gompers (1996), occurs when 
younger venture capital firms seek IPOs for their investee firms earlier than more 
established venture capital firms.  Gompers (1996) collected data from 433VC-backed 
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IPOs in the United States between 1978 and 1987 and compared it with IPO data from 62 
venture capital funds between 1983 and 1993, to discover that younger venture capital 
firms averaged 8 months faster to IPO versus more established firms (e.g., 16 months for 
younger firms and 24 months for established firms).  Additionally, time-to-IPO speed and 
higher fundraising for future funds were positively correlated (Gompers, 1996). 
Several authors conducted an empirical analysis of longitudinal data from global 
stock exchanges (Jia, 2014; Jiang, Cai, Keasey, Wright, & Zhang, 2014; Michala, 2016;), 
continuing the grandstanding phenomena debate nearly two decades after Gompers.  
Michala (2016) stated that while younger venture capital firms had more IPOs, 
established venture capital firms’ IPOs were more prominent and profitable.  Jiang et al. 
(2014) discovered foreign VCs did not exhibit grandstanding behavior, while Chinese 
VCs brought portfolio firms faster to market to bolster their reputations and subsequent 
fundraising.  The authors did not state if the foreign VCs were either younger or from 
more established firms.  Likewise, Jia (2014) highlighted that Chinese venture capital 
funds mature within 5 to 7 years versus the average 10 to 12 years in developed markets.  
Kong, Nitani, and Riding (2016) reported United States VC-backed firms in Canada were 
more than twice as likely to reach an exit and had shorter time-to-IPO than local VC-
backed firms.  These data suggest grandstanding differs between venture capital firms in 
developed and emerging markets.  Further, U.S. VCs may increase the probability and 
speed of Canadian LS firms’ listing on a foreign stock exchange. 
Mergers and acquisitions.  Mergers and acquisitions or trade sales are a highly 
preferable route for VCs to exit their portfolio companies.  VCs in the UK predominately 
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preferred M&A exits and exhibited no signs of grandstanding tactics during their albeit, 
less frequent IPOs (Espenlaub, Khurshed, & Mohamed, 2015).  Bertoni and Groh (2014) 
suggested that the proximity of adjacent countries in the European region encouraged 
subsequent M&A over IPOs for portfolio companies.  Despite the more frequent M&A 
exit route aforementioned, Cumming et al. (2016) argued private portfolio companies 
benefit more from IPOs than M&A because of the added costs of cross country deals.  
Nonetheless, geographical proximity appears to connect stakeholders, increases network 
size, and present new business opportunities.  The proximity effect of U.S. VCs investing 
in Canadian LS firms may encourage M&A exits even if the Canadian LS firm prefers an 
IPO. 
Venture capital portfolio maturity may influence the exit timing and exit route 
preference.  Bhattacharyaa and Inceb (2015) opined that VCs encounter greater pressure 
to exit portfolio companies when the fund nears maturation.  As such, VCs with funds 
nearing expiration tend to choose M&As over IPOs because the former boasts faster 
completion timelines.  Bhattacharyaa and Inceb did not discuss how VCs persuaded or 
pressured management to sell their companies.  Raggozzino et al. (2014) filled this gap 
by empirically demonstrating that VCs with more oversight in their portfolio companies 
and portfolio companies with higher numbers of VCs had a higher likelihood of exiting 
via M&A.  
 Mergers and acquisitions are a popular exit route for Canadian portfolio firms.  
Kong et al. (2016) and Moustakbal (2014) reported Canadian biotechnology firms with 
VC-backing were significantly more likely to exit via M&A than IPO.  The Canadian 
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M&A exit preference is similar to Espenlaub et al.’s (2015) assertion about UK VC-
backed firms M&A exit preference.  Moustakbal (2014) studied Canadian biotechnology 
firm listings from 1996 and 2010 to find that over 50% were not listed a few years later.  
Nearly 30% of the missing firms were attributed to VC-backed M&As and 16% because 
of insolvency (Moustakbal, 2014).  Notably, foreign VCs and highly syndicated VCs 
lowered the potential returns for the participating Canadian VCs during M&A exits.   
Foreign VC investments in Canadian LS firms may provide greater oversight and 
faster exits than local VCs.  While cross-border investments create new investment 
opportunities for U.S. VCs, the political and geographical distance somewhat increases 
investment risk.  Consequently, U.S. VCs must carefully evaluate whether a Canadian LS 
management team can successfully develop and commercialize a drug.  Based on a BPM 
framework, all VCs will continuously improve their evaluation processes in their 
subsequent deals based on the outcomes of their current LS investments.   
Both the IPO and M&A exit route require the LS firm to become a viable 
commercial business or demonstrate significant drug development progress.  Although 
VC-backed firms are faster to IPO, their post IPO performance impacts the VC’s 
reputation.  The VC must select a capable LS management team to develop the drug and 
function independently post exit.  Hence, the management evaluation process ultimately 
impacts the VCs future portfolio fundraising activities and future IPOs.  The LS 
management team evaluation process affects the entire VC investment process and the 
exit potential.  In sum, a successful exit depends on a successful start.  
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Venture Capital Investment Process 
 VCs engage in extensive information collection and evaluation to make sound 
investment decisions.  Venture capital investments include both ex-ante and ex-post 
activities.  Xi and Su-Sheng (2016) described that life sciences investors and 
entrepreneurs typically use the overall strategic direction of the portfolio fund to guide 
the searching, screening, due diligence, monitoring, and harvesting of prospective 
investments.  Reviewing the holistic investment process is central to elucidating the 
position of a single stage, such as evaluating management teams.  
The investment decision is contingent upon the investee firms’ business stage.  
Joshi and Subramanya (2015) detailed that in India, foreign VC firms refrain from early-
stage company investments because of the risk propensity.  Paik and Woo (2014) 
demonstrated a slightly different pattern for local U.S. VCs.  Leveraging more than two 
decades of data from the Thomson Financial Venture Economics database, the authors 
demonstrated that VCs invest more in early-stage firms during economic booms.  Since 
early-stage firms are overall riskier investments than later-stage investments, these data 
suggest VC’s take more risk during economic prosperity.  Economic booms position 
early-stage firms for venture capital investment. 
Investment stages.  VCs progress through several stages or steps throughout the 
lifespan of a deal.  Tyebjee and Bruno (1984) characterized the five sequential steps in 
the venture capital investment process: deal origination (finding the deal), deal screening 
(weeding out the viable proposals), deal evaluation (in-depth assessment or due diligence 
of viable proposals), deal structuring (negotiating the term-sheet), and post-investment 
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activities (monitoring and governance).  Similarly, Ramsinghani (2014) classified 
sourcing and screening, due diligence, investment terms negotiation, post investment 
monitoring, and exits as the main stages in the investment process.  In general, the VCs 
align on the basic investment steps. 
Human capital in venture capital firms directly impacts its capacity to screen 
investments.  de Treville, Petty, and Wager (2014) noted almost 10% of attractive deals 
were not considered because the venture capital firm had human capital resource 
constraints.  Koskinen, Rebello, and Wang (2014) suggested VCs neglect screening a 
deal if the entrepreneur has high bargaining power, which leads to unduly high 
investment demands and eventual premature deal termination.  This implies experienced 
VCs may precipitously reject deals linked to entrepreneurs with high bargaining power.  
Investment decision uncertainty intensifies when the VC does not have or does 
not know how to obtain the necessary information about the portfolio company.  
Achleitner, Braun, Lutz, and Reiner (2014) posited that VC profits were higher in M&A 
exits when the acquirer was from a different industry than the portfolio company.  
Although experienced VCs successfully reported high profits regardless of the buyer’s 
industry (Achleitner et al., 2014).  This implies experienced VCs were superior at 
assessing the various buyers and mitigating adverse selection.  
The VCs investment experience levels benefit deal evaluation.  Brazilian 
researchers noted that when VCs improved their screening skills, their investment 
percentage doubled and the frequency of re-screenings decreased 50% (de Carvalho, 
Netto, & Sampaio, 2014).  Hopp and Lukas (2014) echoed the Brazilians, asserting that 
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VCs leverage their skills to spend less time screening, evaluating, and monitoring their 
investments than inexperienced VCs.  Additionally, VCs consolidate the collective skills 
of their syndicates to save time in the screening phase (de Carvalho et al., 2014).  Fazekas 
and Becsky-Nagy (2015) illustrated that VCs willingly fund high risk start up and early-
stage technology companies when they negotiate higher involvement in management and 
operations of the firm.  Similarly, Joshi and Subrahmanya (2015) contended that 
information asymmetry is higher when the VC is foreign because distance increases 
barriers to VC monitoring and oversight.  Therefore, increased oversight reduces 
information asymmetry.  
Life sciences investment criteria.  Soenksen and Yazdi (2017) conducted a 
global qualitative case study with 68 investors to formulate a stage-gate model unique to 
the life sciences industry.  Although the model represented several distinct stages and 
tasks specific to the LS industry, the overall framework was consistent with the core 
investment steps proposed by other scholars.  The weighted pre-evaluation tool included 
items such as clinical and epidemiology, technology and concept, market assessment, 
intellectual property, regulatory strategy, funding, scope, business plan, risks and 
mitigation, and overall “gut feeling.”  Lehoux, Miller, Daudelin, and Urbach (2016) 
noted VCs describe assessing management based on their “gut feeling.”  Management did 
not receive additional weighting or elaboration aside from team experience. 
Some studies have included management team criterion.  Afful-Dadzie and Afful-
Dadzie (2016) addressed the management team criterion weighting gap in their 
theoretical fuzzy technique for order preference by similarity to ideal solution (TOPSIS) 
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venture capital decision-making model.  While, the decision criteria included dimensions 
ranging from management’s personality and experience (Afful-Dadzie et al., 2016), the 
overall model will require iteration, validation and practical applicability considerations 
before mainstream adoption.  Similarly, Gordon (2014) published an eight stage-gate 
model in venture philanthropy, a growing socially conscious venture capital, which 
outlined management evaluation.  The specific criteria for management were integrity, 
strengths and weaknesses, leadership capability, and pragmatism (Gordon, 2014).  
Nevertheless, there is little consensus about how VCs should quantify difficult to 
measure qualities such as integrity or leadership in the evaluation process. 
Lehoux, Miller, Daudelin, and Urbach (2016) interviewed VCs in Canada over 5 
years to understand how VC’s assess health technology companies, ranging from deal 
valuation, protecting and ensuring the company’s success, and ensuring maximum exit 
profitably.  In the deal valuation stage, VCs rely on a combination of mental logic and 
intuition or “gut feel” to assess the management team (Lehoux, et al., 2016).  Some 
evaluation techniques, such as verbal protocol analysis, outright disregard management 
evaluation (Monika & Sharma, 2015).  Motta, Garcia, and Quintella (2015) compared 
five invested and five rejected companies in Brazil to devise a protocol for prioritizing 
venture capital investments.  While the rejected companies did not meet most VC’s 
selection criteria, such as technology (patents and peer-reviewed publishing) and market 
dynamics (Motta et al., 2015), the absence of management evaluation criteria was 
conspicuous.   
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Although some authors (Afful-Dadzie et al., 2016; Gordon, 2014; Lehoux et al., 
2016) included management criteria in the investor evaluation criteria for LS firms, the 
VCs reliance on intuition suggests their management evaluation process is conjectural.  
As recommended in the BPM framework, VCs have an opportunity to identify and design 
a transparent management assessment protocol to minimize their dependence on 
intuition.  A standardized evaluation model will allow VCs to judiciously measure, 
analyze, and optimize future LS investments in a forward-looking manner.    
Management characteristics.  Researchers have inculcated the importance of 
management in the venture capital investment process for several decades.  Kryzanowski 
and Giraldeau (1977) asserted that management criteria was the critical factor for 67% to 
80% Canadian and American VCs.  Incompetent management also causes VCs to reject 
proposals.  Johnson (1979) observed that in over 600 VCs, unsatisfactory management 
competencies and unattractive return potential were the most common reasons for 
proposal denial.  More recently, data from an Italian angel investment group suggested 
business angels excluded deals with tenuous management teams during the screening 
phase (Croce, Tenca, & Ughetto, 2017).  Although the authors did not present an industry 
sub-analysis, the medical/biotech sector represented 33% of investments and 45% of 
investments dollar amounts in the Italian angel investment group (Croce et al., 2017), 
suggesting business angels invest less frequently yet more substantially in the sector.  
Gompers, Gornall, Kaplan, and Strebulaev (2016) advanced scholarship by 
surveying 885 VC firms, who pronounced that technology was secondary to the 
management team during the screening phase.  Specifically, 95% of VCs rated 
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management (e.g., ability, experience, and teamwork) as central to their investment 
decision compared to the business model (74%) or the market (68%) (Gompers et al., 
2016).  Importantly, VCs working with health care/biotechnology firms considered 
management’s industry experience of utmost importance (Gompers et al., 2016).  In sum, 
since the 1970s, perceptions about LS management teams continue to impede VC’s 
investments. 
Business angels (BA) and crowdfunders are two other investor groups which 
consider management team qualifications.  BA’s are private, wealthy individuals who 
invest in seed and early-stage companies for capital gains, altruism and personal interest 
in the venture (Hsu, Haynie, Simmons, & McKelvie, 2014).  BAs underscore the 
importance of the management team on investment success and often form immediate 
impressions or “gut feel” (Huang & Pearce, 2015), similar to VCs.  BAs value the 
management teams’ education, industry experience (Becker-Blease & Sohl, 2015) 
business preparedness (Maxwell & Lévesque, 2014; Rostamzadeh, Ismail, & Zavadskas, 
2014), equanimity (Parhankangas & Ehrlich, 2014) and passion (Hsu et al., 2014).  
Harrison, Mason, and Smith (2015) noted that experienced BAs made investment 
decisions expeditiously compared to more novice BAs.  Considering many VC 
investments include parallel BA investments, these authors suggest management team 
characteristics are an equally important consideration for both groups of investors.  
Investment sources are evolving to include a global investor base (Salomon, 
2016).  Crowdfunding is a means for entrepreneurial companies to request funding or 
donations, predominantly internet-based, from several small investors (Belleflamme & 
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Lambert, 2014) in exchange for future products or equity (Mollick, 2014).  Ahlers, 
Cumming, Günther, and Schweizer (2015) discovered equity crowdfunding investors 
favor management teams with formal business education.  Conversely, Lukkarinen, 
Teich, Wallenius, and Wallenius’ (2016) contended that crowdfunders are on average 
less informed and not as accomplished as VCs and BAs and therefore do not have the 
same high expectations of management teams.  The differences between VCs, BAs, and 
crowdfunders suggest the motivation and investment objectives affect the emphasis 
placed on management teams.  
Integrity.  Evaluating an entrepreneur’s integrity is open to interpretation.  A VC 
might test a prospective manager’s integrity by acting in an unethical manner.  In a study 
of 65 midwestern U.S. VCs, Drover, Wood, and Fassin (2014) demonstrated that most 
entrepreneurs rejected financing from unscrupulous VCs.  However, during periods of 
financial duress, some entrepreneurs considered alliances with unscrupulous VCs (Drover 
et al., 2014), a sign of vulture financing.  In spite of exclusivity agreements, financial 
duress may motivate some management teams to prospect other venture capital firms 
(Casamatta & Haritchabalet, 2014).  In general, entrepreneurs are more willing to forego 
an investment deal over compromising their integrity.  
Sales and operational skills.  Managerial competence is salient to firm outcomes.  
Entrepreneurial competence is inversely related to VC monitoring (Mishra & Zachary, 
2015).  When management demonstrates strong capability, investors feel less pressure to 
supervise business operations.  Investors value managerial teams’ sales and operations 
skills (Morrissette & Hines, 2015) because those skills increase the likelihood of 
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achieving business objectives (Bernstein, Korteweg, & Laws, 2017).  Similarly, Lovas 
(2015) concluded that investors desire managers with strong business acumen.  Bernstein 
et al., (2017), Morrissette & Hines (2015), and Lovas’ (2015) empirical studies affirm the 
significance of sales and operations skills.  
Experience.  Whether a business thrives or fails is contingent upon its 
management’s experiential foundation (Dhochak & Sharma, 2016).  In a study of 346 US 
entrepreneurs, Miskin and Rose (2015) observed that business experience predicted 
business survival for at least two years.  In turn, business survival correlates with higher 
ownership, self-efficacy, and domain expertise (Miskin & Rose, 2015).  Notably, Eastern 
European VCs appraise managements’ proficiency through the content and style of their 
presentations (Zinecker & Bolf, 2015).  Chan and Park (2015) demonstrated that high 
visual aid usage, including selecting blue over red colors, was associated with favorable 
VCs funding decisions.  Other VCs observe and judge the management teams’ verbal 
skills, business experience and actions, to estimate investment risk (Joshi & 
Subrahmanya, 2015).  
Education.  Previous authors established that education and industry experience 
are important for management.  Examining data from 117 financing rounds in 84 
biopharmaceutical firms, Patzelt (2010) explained that CEOs with business education 
receive more VC financing when the management team is larger.  CEOs with significant 
industry experience receive more VC investment with when they have smaller 
management teams (Pazelt, 2010).  Behrens, Patzelt, Schweizer, and Bürger (2012) 
specified biopharmaceutical firm managers educated in business, law, medicine, and 
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biosciences acquire more VC financing only when the firm is younger.  These authors 
indicate VCs draw conclusions contingent upon the configuration of the management 
teams’ education and size, and firm age.  
Team heterogeneity.  Miloud, Aspelund, and Cabrol (2012) determined that VCs 
preferred to invest in prospective firms with all key management positions filled, 
preferably with several founding members.  The personalities of management team 
members are also relevant to VC impressions (Carlos Nunes, Gomes Santana Félix, & 
Pacheco Pires, 2014).  Although diverse management teams have a higher likelihood of 
personality struggles (Cai, Liu, & Yu,2013), VCs prefer to invest in heterogenous teams 
(Sahayam, Cho, Kim, & Mousa, 2016; Vogel, Puhan, Shehu, Kiger, & Beese, 2014).  In 
aggregate, more diverse (e.g., education, gender, culture) and cross functionally 
experienced management teams possibly have lower chances of groupthink behaviors.  
Conflict management skills.  The potential for conflict between VCs and 
management is high.  The spectrum of activities, from the proposal stage, negotiating 
term-sheets, and yielding control to VCs, increases the likelihood of conflict 
(Mohammad, Minai, & Lucky, 2014).  Khanin and Turel (2015) reported that 
management regret making deals with VCs when conflict occurs, so they modify their 
future funding strategy by approaching other financiers.  VCs could evaluate 
management’s conflict management skills during the screening processes, however, post-
investment, both sides should remain vigilant about clear communication.  
 Self-efficacy.  Several authors researched the implications of an entrepreneur’s 
degree of self-efficacy.  Baron, Franklin, and Hmieleski (2016) posited that managers 
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who demonstrate resilience and confidence in their abilities were happier and reported 
lower stress levels.  While Baron et al.’s conclusions reflected the beliefs of 
predominately Caucasian males, Zou, Chen, Lam, and Liu (2016) explored a similar 
study with Chinese entrepreneurs.  Self-efficacious entrepreneurs were more self-
confident and cooperative with their VCs (Zou et al., 2016).  In contrast, Robinson and 
Marino (2015) observed that some degree of hubris is inherent in entrepreneurs who start 
businesses.  VCs should consider the combination of humility and confidence they desire 
in their management teams and acknowledge that most entrepreneurs are self-assured.  
Trust.  Honesty (Nokolova, Möllering, &Reihlen, 2015), goodwill, and 
compassion (Cox, Kerschbamer ,& Neururer, 2016) are trust producing behaviors.  
Although trust is important in business relationships, measuring trust is less 
straightforward (Batkaikhan, 2017).  Bottazzi, Da Rin, and Hellmann (2016) addressed 
trust by employing a Likert scale, asking VCs to rank their levels of trust for people in 
various European countries.  A 1% increase in trustworthiness increased the likelihood of 
investment by 7%, with the highest trustworthiness for Nordic citizens and the least for 
Italy and Portugal (Bottazzi et al., 2016).  
When entrepreneurs have Machiavellian-like tendencies, VCs eventually learn the 
truth.  Pollack and Bosse (2014) claimed investors do not immediately terminate a deal 
when they uncover investee falsification.  Rather, the financial losses from terminating a 
deal impacts the VC’s willingness to forgive the dishonesty (Pollack & Bosse, 2014).  
Middelhoff, Mauer, and Brettel (2014) advanced the literature on how investors built 
trust with entrepreneurs.  In the post-investment phase, a VC’s kindness and empathy 
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levels impact the relationship (Middelhoff et al., 2014) and possibly firm outcomes.  
Future studies should address the relationship between firm performance and the VC’s 
benevolence towards the management team.  If VCs and management teams must co-
exist in a reciprocal relationship, they must build tolerance for each other’s shortcomings.  
An entrepreneur’s facial appearance could impact trust perceptions.  Ewing, 
Caulfield, Read, and Rhodes (2015) argued that judging facial appearance for 
trustworthiness is an intrinsic reaction for most humans.  Five-year-old children begin to 
discriminate untrustworthy faces from trustworthy faces (Ewing et al., 2015).  Ormiston, 
Wong, and Haselhuhn (2017) suggested oblong or thin faced males were considered 
more capable and honest than others. Brooks, Huang, Kearney, and Murray (2014) 
chronicled the effect of physical appearance, where investors were partial to attractive 
male presenters.  Although the evidence that facial appearance impacts investment 
decisions requires further substantiation, the potential for bias is apparent.  
Gender.  Ceterus paribus, Bigelow, Lundmark, McLean Parks, and Wuebker 
(2014) demonstrated using student participants, that IPO firms with female CEOs 
received four-fold fewer recommendations for investments than males.  Moreover, male 
participants did not prefer females for CEO positions, nor did they consider any benefits 
of female inclusion in the management team (Bigelow et al., 2014).  Extending the 
gender bias research to VCs, Tinkler, Bunker Whittington, Ku, and Davies (2015) 
showed that VC penalized female leaders lacking qualifications with more significantly 
reduced venture capital investments than males, although the effect was slightly mitigated 
if the females and the VC were socially connected.  In contrast, Thébaud (2015) 
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contended VCs perceived females in both the US and UK who engaged in solving 
business problems as capable entrepreneurs.  VCs could reflect on their investment 
histories for evidence of gender bias.  
Female VCs also experience systematic gender bias.  Gompers, Mukharlyamov, 
Weisburst, and Xuan (2016) analyzed gender effects in US venture capital firms. First, 
5.4% and 4.6% of total investments and IPOs included a female VC, respectively.  
Second, 59% of females expressed gender bias in their venture capital careers.  Third, 
female VC’s investment outcomes were 15% lower than their male contemporaries, 
possibly as consequence of less inclusion and collegial support.  Collectively, the 
evidence suggests gender bias for both female VCs and female entrepreneurs is insidious.  
Culture.  Cultural differences may impact the investment process.  Nahata, 
Hazarika, and Tandon (2014) explored 9,813 VC investments in 30 developed and 
emerging economies, indicating cultural distance increases VC due diligence due to 
higher information asymmetries.  Increased due diligence led to more VC led exits 
(Nahata et al., 2014).  Moore, Payne, Bell, and Davis (2015) advised that European 
companies seeking venture capital financing should minimize perceptions of cultural 
differences.  Bengtsson and Hsu (2015) conducted a regression analysis to report a 
positive relationship between cultural similarity and VC investment.  Sharing similar 
cultural background to a VC in the US increased the probability of investment by 21%; 
however, those investments were less successful (Bengtsson & Hsu, 2015).  Cultural 
similarities may introduce bias in investment decisions.  
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Like Bengtsson and Hsu (2015), Gompers, Mukharlyamov, and Xuan (2016) 
concluded that cultural affinity within venture capital syndicates leads to less successful 
exits.  When VCs syndicated with ethnically similar VCs, the likelihood of exiting the 
deal profitably decreased 32% (Gompers et al., 2016).  For East Asian VCs (60% 
decrease) and Jewish VCs (25% decrease), the culturally homogenous penalty was even 
more pronounced.  Cultural homogeneity within VC firms and the VC-entrepreneur 
relationship may increase vulnerabilities towards groupthink, which could impact exit 
outcomes.  Future research could investigate the reasons for decreased performance, such 
as blurred friendship-business boundaries, reduced professionalism, or groupthink.  
Evaluating a LS management teams’ drug development capabilities amidst a 
plethora of criterion is a formidable task for VCs.  VCs must collect and evaluate a wide 
depth and breadth of information about the management team in addition to other 
investment criteria.  While VCs frequent rely on their “gut feeling” or intuition, 
unconscious bias, such as gender preferences, cultural similarities, alma mater, and 
entrepreneur attractiveness can influence their decisions to the detriment of future returns.  
Moreover, because gut feel is neither transparent or documented, the VC cannot 
reasonably measure or predict an investment’s outcome.  A BPM framework can assist 
VCs to disentangle intuition from rigorous selection process.  VCs can reduce ambiguity 
by redesigning their evaluation processes such as specific criteria used to assess 
management teams and the assessment protocols.  Improving the criteria and protocols 
will help VCs identify success factors for a profitable exit and to make better investment 
decisions in the future. 
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Life Sciences  
Life science firms make a significant contribution to the development of 
innovative medicines.  Life science companies develop commercially viable technologies 
for human health, such as medical devices, pharmaceuticals, and biologics (Maak & 
Wylie, 2016).  Authors frequently imply biotechnology when discussing LS companies 
(Carrick, 2016).  Biotechnology and biopharmaceuticals are a subset of the LS industry 
which involves research in several disciplines (e.g., genetics, molecular biology, cell 
biology, and immunotherapy) to design and develop therapeutics for human diseases 
(Bratic et al., 2014; Huggett, 2014).  
Life science firms (including pharmaceutical and biotechnology) and financiers 
form specialized knowledge or clusters in a few regions.  The localization of venture 
capital and other investment firms are essential for advancing research and developing 
biotechnology ventures in these clusters (Florida & Mellander, 2016; Kim, 2015).  
Canada produces reputable scientific talent who reside in select biotechnology clusters, 
predominately Vancouver, Toronto, and Montreal (Canadian Venture Capital 
Association, 2017).  Boston, San Francisco, Seattle, Cambridge, and San Diego represent 
thriving biotechnology clusters in the U.S., with a critical mass of universities, 
government research laboratories, venture capital firms, and entrepreneurial firms 
(Francisco, 2014; Francisco, 2015).  Venture capital firm and LS firm proximity, 
linkages, and cooperation in these clusters translate technical know-how into new 
biotechnology enterprises.  
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Drug Development  
Progressing a drug from discovery, regulatory approval, and commercialization is 
an extensive and arduous process.  Regulatory agencies require new molecular entities to 
undergo pre-clinical pharmacokinetic and pharmacodynamic studies in animals before 
human studies (Pestonjamasp, 2016).  Following satisfactory preclinical studies, 
companies conduct human clinical trials (phases I, II, III), which progress from proof-of-
concept early phase trials through to safety and efficacy registrational trials (Bratic et al., 
2014).  The entire process takes 10 to 15 years to execute (Bratic et al., 2014), including 
regulatory review waiting periods. 
Manufacturers must account for regulatory agency review timelines.  
Pestonjamasp (2014) observed the U.S. FDA review timelines shortened since 2008, 
although still require over one year for new drug application (NDA) reviews.  U.S. FDA 
initiatives such as the Breakthrough Therapy designation for serious diseases reduced the 
NDA review period to 60 days (Darrow, Avorn, & Kesselheim, 2014).  Similarly, the 
European Medicines Agency (EMA) and Health Canada accelerates application reviews, 
150 days and 180 days, respectively, for qualifying treatments (Alqahtani, 
Seoane‐Vazquez, Rodriguez‐Monguio, & Eguale, 2015; Lexchin, 2015).  Alqahtani et al. 
(2015) contended that the differences between regulatory agency timelines and 
requirements increase complexities for drug manufacturers.  Recent regulatory agency 
initiatives could be a harbinger for shortened approval timelines in the future. 
Costs.  Drug development capital costs are formidable and increasing.  DiMasi, 
Grabowski, and Hansen (2016) specified that the capitalized R&D costs for the entire 
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drug development process is $2870 million USD.  While clinical trials consume most of 
the R&D budget (DiMasi et al., 2017), Rao (2017) argued that increased clinical trial 
spending does not mitigate risk or de-risk the drug development process.  Despite the 
surmounting costs and high risk, Pitts (2015) contended that ongoing health innovations 
(e.g., drug development) are critical for reducing health care expenditures and improving 
human health conditions.  Gautam (2015) suggested companies could reduce drug 
discovery and development costs up to 75% by leveraging scientific and operational 
capabilities in emerging markets such a Korea, China, and India.  Although companies 
can gain cost savings from outsourcing part of their R&D activities to emerging markets, 
LS management teams must weigh all the risks and benefits. 
Valuation.  An investigational new drug’s future earnings potential is a chief 
concern for management and investors.  There is little consensus on methods and input 
parameters in LS valuation, however, discounted cash flow and real options are 
sometimes applied (Bogdan & Villiger, 2010).  Pestonjamasp (2015) contended net 
present value (NPV) is the main calculation tool used to quantify expected returns, 
expenditures, and risk parameters.  NPV involves determining an investment’s present 
value based on future cash flows (Pestonjamasp, 2015).  Bratic et al. (2014) described 
several risks in NPV calculations, such as errors in risk parameters, overestimating 
market potential, and underestimating the competition.  Iacovides (2016) illustrated an 
alternative biotechnology valuation model for VCs, where the VC’s ownership and 
investment amounts increase as drug development progresses from phase I to phase III.  
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While a shift from NPV to other valuation models is imminent, NPVs long-term utility 
and adoption remains unclear. 
Understanding an asset’s market potential is imperative during early phases of 
drug development.  Gehr and Garner (2016) suggested that management should identify 
the commercial potential of a pharmaceutical asset early.  Bratic et al. (2014) observed 
valuators typically include market size, market share, competition, and growth potential 
in a company’s valuation.  Giovinazzo (2015) added that early-stage biotechnology 
companies should incorporate end-user (e.g., physicians, patients, payors) feedback early 
in the drug development process.  Mullard (2014) highlighted that while many experts’ 
forecasts fall short of actual sales performance, in aggregate, the pharmaceutical industry 
underestimates the value of its blockbuster treatments.  Early in the company’s lifecycle, 
LS management teams should build their forecasting capabilities and continue to build 
relationships with major stakeholders. 
Intellectual property.  A VCs decision to finance one company versus another 
may affect which innovations companies introduce in the market.  Lehoux et al. (2016) 
articulated that VCs in Canada are instrumental in medical technology and health care 
innovations because of their financial investments, oversight, and leadership in early-
stage businesses.  Likewise, Tian and Wang (2014) found experienced VCs were more 
inclined to accept failure and led portfolio firms (technology and biotechnology) to file 
more patents and had more frequent publication citations than other VC-backed firms.  
Patents may serve as a proxy for innovation.  Hottenrott, Hall, and Czarnitzki 
(2016) examined patent filing and investments in R&D stage firms from several 
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industries in the Flemings region from 2000 to 2009.  Overall, patents had more 
investment implications for smaller firms (Hottenrott et al., 2016).  In a UK high 
technology company, Smith and Cordina (2015) reported a direct relationship between 
the company’s patenting activity and VC investment amounts.  Other researchers have 
also reported VCs direct relationship to technology or biotechnology firms’ patenting 
activity (de Rassenfosse & Fischer, 2016; Haeussler, Harhoff, & Mueller, 2014).  In sum, 
while most researchers agree on a relationship between VC and patenting activity, 
causality is uncertain. 
Some VCs might not encourage patent generation after the initial investment. 
Hoenen, Kolympiris, Schoenmakers, and Kalaitzandonakes (2014) posited that the value 
of a patent in a biotechnology company depends on the financing round or development 
stage.  Specifically, while patents attracted an additional USD 557,333 in the first round, 
subsequent patents did not generate future venture capital financing (Hoenen et al.).  
Likewise, Block, De Vries, Schumann, and Sandner (2014) examined over 50000 venture 
capital financing rounds from 1998 to 2007 to discover VCs invested more in firms with 
trademarks predominately in the first financing round because trademark applications 
positively signal management’s foresight and business strategy.  These data suggest some 
VCs view patents as a screening signal.  
Hoenig and Henkel (2015) surveyed technology (e.g., biotechnology and 
cleantech) focused German and US VCs to find an alternative result.  VCs considered a 
firm’s network and management experience as more important indicators of quality than 
patents during the screening stage (Hoenig & Henkel, 2015).  Correspondingly, 
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Knockaert, Huyghe, and Clarysse (2014) clarified European VCs with technical 
experience would value patents more than a VC with general business experience.  
Knockaert et al. suggest industry specific technical experience may augment the VC’s 
comprehension and value of the patent.  Overall, VCs do not appear to value patents 
homogenously. 
Capabilities.  The increasing drug development complexity, from molecule 
discovery to commercialization requires management teams with skill-set breadth and 
depth.  Gunn, Masterson, Lorton Jr. and Baronet (2016) reported that a biopharmaceutical 
firm’s intellectual property, science, regulatory expertise and fundraising abilities are the 
most important capabilities for innovation and competitiveness.  Schuhmacher, 
Gassmann, and Hinder (2016) determined that research collaborations, strategic alliances, 
and open innovation with academia or other biopharmaceutical firms are becoming the 
norm for building technological capabilities (e.g., drug targets, animal models, or disease 
expertise).  Early-stage LS management teams must balance fostering collaborative 
networks while maintaining a competitive advantage unique to their firm.  
Management skills.  Management skill requirements change precipitously as drug 
development advances from laboratory testing, to human clinical trials, and 
commercialization.  McLaughlin (2015) suggested humility, problem-solving attitudes 
and an unwavering focus on patients distinguish the best LS management teams.  Gehr 
and Garner (2016) stated that to attract investment, scientific entrepreneurs should master 




Financial acumen.  VCs will scrutinize a management team’s financial acumen. 
Jambulingam, Schellhorn, and Sharma (2016) posited that there is a direct correlation 
between management skills and financial performance of a firm.  Meyers (2014) 
highlighted that business and entrepreneurship training programs are slowly increasing 
for biomedical professionals.  Miron-Shatz, Shatz, Becker, Patel, and Eysenbach (2014) 
suggested VC involvement in medical conferences could help scientists learn fundraising 
and business skills.  Life science management teams comprising mainly of scientists and 
researchers could be deficient in their financial management skills.  However, they can 
develop their business skills with support from VCs and training programs. 
Regulatory expertise.  Strong management teams demonstrate knowledge of 
regulatory agency (e.g., FDA, EMA and Health Canada) rules, requirements, and 
nuances.  Schueler and Ostler (2016) reported that VCs assess the management teams’ 
regulatory requirement knowledge and navigation savviness during their due diligence 
process.  Sacks et al. (2014) noted that suboptimal dosing, poor study design, and 
efficacy concerns were reasons for FDA rejections.  Woloshin, Schwartz, Frankel, and 
Faerber (2014) recommended companies could circumvent NDA rejections by seeking 
FDA special protocol assessment, certifying more robust study designs and better 
primary endpoints.  Life science management teams should swiftly close any knowledge 
gaps on regulatory requirements and demonstrate their regulatory know-how to improve 
investor confidence. 
Risk is intrinsic to venture capital deals.  Chassot, Hampl, and Wüstenhagen 
(2014) reported VCs evade investments with high regulatory risk.  Additionally, U.S. 
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venture capital investments from 1990 to 2008 revealed VCs mitigate risk in the clean 
energy sector (high regulatory risk) by syndicating and investing in later stage companies 
(Petkova, Wadhwa, Xin, & Jain, 2014).  These authors suggest VCs may choose lower 
equity stakes in some industries to hedge their regulatory risk. 
VCs must dissect and analyze which factors constitute a capable or high potential 
LS management team.  The drug development process is expensive, lengthy, complex, 
and highly regulated.  Life science management teams are typically entrepreneurial, 
scientific researchers whose main expertise are in LS disciplines.  Life science 
management teams build networks, alliances, locate suppliers, raise financing, learn 
regulatory requirements, intellectual property, and hire talent for different departments.  
Mastering the drug development process (e.g., clinical trials, regulatory requirements, 
and payors), building a business, managing investment funds, and commercializing a 
product requires a cross functional team with various skill sets, leadership competencies, 
time, and trial and error.  Additionally, LS management teams must keep abreast of 
advances in scientific research and other innovations.  The VC evaluation process should 
account for the complexity of the drug development process and the broad expertise 
requirements.  
Venture Capital Value Proposition  
VCs  invest in portfolio companies in exchange for equity and governance 
(Gompers & Lerner, 2001) though often with significant differences or preferences 
between VC firms (Hochberg, Lindsey, & Westerfield, 2015).  Pre-investment, VCs who 
are satisfied that they will have sufficient governance and monitoring of the prospective 
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firm are more likely to invest (Drover, Wood, & Payne, 2014).  Although investees must 
give some control to VCs in exchange for capital, VCs offer other resources, namely, 
certification, mentoring, and networks.  
Monitoring.  VCs deliberate the monitoring and governance process as early as 
screening the phase.  Farag, Mallin, and Ow-Yong (2014) suggested monitoring activities 
increase with higher investments and led to better portfolio firm performance. Similarly, 
Proksch et al. (2017) suggested venture capital companies are highly engaged in 
supporting ventures with financial and human capital issues as well as to establish strong 
governance mechanisms to reduce information asymmetries between founders and 
investors.  A combination of strong VC governance mechanisms and quality management 
are requirements for firm outcomes.  
Certification.  A venture capital investment may send a quality signal to the 
broader investment community about the entrepreneurial firm.  Guerini and Quas (2016) 
empirically demonstrated an increase in the probability of receiving additional venture 
capital investments after receipt of government venture capital in Europe.  Ogura (2016) 
concurred that the VC’s presence provided a certification signal, thereby lowering the 
risk profile of IPO companies.  Conversely, Miloud (2016) reasoned that adverse 
selection artificially intensifies the certification benefits towards inexperienced portfolio 
companies who seek venture capital more than seasoned entrepreneurs.  More seasoned 
entrepreneurs use their experience to attract other forms of investment.  Overall, the VC’s 
certification value-add may not be ubiquitous. 
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Mentoring.  The VC may transfer general business and industry-specific 
knowledge to portfolio companies.  Venture capital affiliation offers mentorship for both 
experienced and inexperienced investees (Plummer, Allison, & Connelly, 2016).  
Pierrakis and Saridakis (2017) reported that while some UK government VCs were 
proficient at screening prospective deals, they lacked coaching skills to support patenting 
activity post-investment.  Meglio, Mocciaro Li Destri, and Capasso (2017) contended that 
the best VCs practice robust coaching processes and procedures accumulated from their 
past experiences (especially industry experience).  Importantly, the coaching skillset may 
enhance portfolio firm outcomes (Meglio et al., 2017).  Singh, Aggarwal, and 
Cojuharenco (2015) reported that VCs with amateur IT knowledge demonstrated more 
hubris and confidence than VCs with modest IT proficiency.  These authors suggest that 
VC’s with limited industry and domain expertise may disguise their shortcomings with 
overconfident behaviors.  Scholars have not elucidated the education and experience 
requirements for VCs investing in LS companies.   
Some countries allow banks to offer debt equity such as venture capital.  Ye 
(2015) reiterated that regulations limit countries like Denmark, Sweden, Canada, and the 
United States banks on the amount of debt equity financings they can offer.  Ye argued 
during investment scenarios with unusually high information asymmetry and heavy R&D 
expenses, investors (including European banks) can negotiate milestone payment plans 
instead of upfront lump sum payments.  The author neglected to account for the other 
value-added benefits and oversight VCs provide, which are not easy for banks to mimic. 
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Finally, Wong (2014) suggested governments adopt tax credits policies (e.g., risk 
premiums) to compensate VCs for the high risk inherent in start-up equity deals. 
Network.  Many entrepreneurs covet access to a wider network (e.g., 
entrepreneurs, financiers, experts, lawyers, and investment bankers) to increase their 
chances of success, even at the expense of valuation (Falik, Lahti, & Keinonen, 2016).  
VCs grant investees access to their networks.  Forming syndicates multiplies VC 
networks (Bellavitis, Filatotchev, & Souitaris, 2017).  Bellavitis, Filatotchev, and 
Kamuriwo (2014) demonstrated that while all networks are important, VC-backed 
companies benefit more from external networks than contacts from the same industry.  
Concurrently, Cox Pahnke, McDonald, Wang, and Hallen (2015) cautioned these 
network linkages, direct or indirect, can inadvertently disclose pertinent information to 
competitors.  In a retrospective analysis of medical device product launches, 
innovativeness and the number of associations were inversely related (Cox Pahnke et al., 
2015), suggesting more connections could decrease new product creations. Taken 
together, network composition and network reach have implications for its utility and 
added risks for both the VC and the VC-backed firm. 
Venture capital investments are embedded with risks.  In addition to capital, VCs 
may provide certification, network, and mentoring value-add to their portfolio firms to 
increase their chances of success and mitigate risk.  An ideal venture capital deal should 
afford mutual benefits and positive-sum outcomes for both parties.     
The review of the literature illustrates the VC investment process and the drug 
development process.  Drug development is about building a health care enterprise to 
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treat human health conditions.  The chosen conceptual framework, BPM, is based on the 
premise is that if a VC continuously improves his evaluation processes, then he increases 
his chances of investing in a successful firm.  As such, improving evaluations of a LS 
management teams’ capability for developing a drug can help the VC select winning 
investments.  To improve evaluations of LS management teams, VCs should inventory 
their own drug development expertise and apply their know-how during the evaluation 
process and post-investment activities.  Increasing investments will help VCs enhance 
their LS investment skills.  With greater experience, VCs can identify best practices, 
management capabilities and patterns which correspond to success.  Some VCs may help 
improve a LS management teams’ limitations, such as business management, financial 
literacy, and networks.  After a review of the literature, the need for new research related 
to improving VCs evaluation processes of LS management teams’ drug development 
capabilities proved necessary.  
Transition  
In Section 1, I presented (a) the background of the problem, (b) the problem and 
purpose statements, (c) the research question,and (d) the research methodology and 
design. I presented information on the conceptual theory that underpins my study: 
business process management.  In Section 2, I detail the role of the researcher, the case 
study method and qualitative research design, population and sampling used in the study, 
ethical research, data collection, data analysis, research validity and reliability.  In 
Section 3, I present the findings and the significance of this study as it relates to 




Section 2: The Project 
In Section 2, I outline how I conducted this study on VC process improvement 
strategies for evaluating LS management teams.  I restate the purpose statement and 
elucidate (a) the role of the researcher, (b) study participant selection, (c) the research 
methodology and design, (d) study population and sampling, (e) ethical research 
considerations, (f) data collection, (g) data analysis techniques, and (h) reliability and 
validity considerations. 
Purpose Statement 
The purpose of this qualitative multicase study was to explore effective strategies 
VC partners use to improve their evaluation processes of LS management teams’ drug 
development capabilities.  The target population included American and Canadian 
venture capital firm partners who successfully improved their evaluation processes of at 
least one Canadian LS management teams’ drug development capabilities in the past 10 
years.  The implications for positive social change include improving investment 
decisions and stakeholder returns, which may enhance investment in LS firms for 
enabling development of innovative therapies to treat illnesses in areas of unmet medical 
needs for improving patients’ lives. 
Role of the Researcher 
I was the data collection instrument in this study.  In qualitative studies, the 
credibility, dependability, and transferability of the data rely on the integrity of the 
researcher (Noble & Smith).  Researchers influence the study’s integrity with their past 
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experiences, research skills, and communication skills (Berger, 2015).  My role as the 
researcher included personally interacting with the research participants to (a) solicit 
participation, (b) schedule interviews, (c) conduct interviews, (d) member check, and (e) 
other activities, as required, during the research process.  Notably, before conducting this 
study, I had no relationships or interaction with the participants.  
Although I had no direct prior experience with the participants or venture capital, 
I had extensive work experience in the LS industry.  My experience in both 
biotechnology firms and large pharmaceutical firms spans several areas of drug 
development, namely drug discovery, clinical trial management (Phases I to IV), 
marketing, market access, medical affairs, and sales training.  Launching new 
pharmaceutical products (including preapproval and postapproval activities) in clinical 
research and medical affairs shaped my impression of factors for commercial success.  
Researchers are responsible for abiding by a code of ethics and to protect study 
participants.  The Belmont report outlined the basic ethical principles for research in 
human subjects including respect for persons, beneficence, and justice (U.S. Department 
of Health, Education & Welfare, 1979).  I followed the ethical guidelines described by 
the Walden University Internal Review Board (IRB), obtained informed consent, and 
kept participant identity and geographical locations confidential and anonymous with 
identification codes.   
Researchers must obtain informed consent to ensure participants are fully 
informed about any risks and benefits of study participation (U.S. Department of Health, 
Education & Welfare, 1979).  I obtained informed consent from participants and ensured 
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they understood the risks and benefits of participating in this research study. To remain 
transparent, my intent was to disclose any potential connections, conflicts of interests, or 
other conditions that might lead to misperceptions among participants.  
I did not lead participants to believe that involvement in this research project 
would lead to new investments or reveal insider information.  Study participants are often 
concerned about the loss of privacy during the research process (Bonevski et al., 2014). 
My intent was to make efforts to conduct the interviews in private spaces and to protect 
the participants’ confidentiality and anonymity at all times.  
As the researcher, I was the data collection instrument.  Consequently, my 
previous experience in the LS industry had the potential to introduce bias into the study.  
Sutton and Austin (2015) suggested a degree of bias is inevitable in qualitative studies 
because researchers analyze data through the lens of their previous experiences and pre-
existing beliefs.  The researcher’s proximity to the subject matter and participants may 
affect the data collection and interpretation (Berger, 2015).  Identifying biases and 
assumptions helps the researcher achieve neutrality during the research process (Austin & 
Sutton, 2014; Darawsheh & Stanley, 2014).   
Researchers can mitigate bias in several ways.  First, researchers must remain 
objective and neutral when communicating with the participants.  Second, researchers 
must ensure interview questions align with the research question(s).  The researcher has a 
responsibility to ensure she is interpreting and analyzing raw data in the intended context 
(Moravcsik, 2014).  When appropriate, researchers may ask additional clarifying and 
probing questions about their processes or experiences.  Third, transcripts and use of 
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qualitative data analysis software for coding and thematic analysis will help mitigate bias.  
Member checking ensures transcripts are accurate and verifiable with the intended 
meaning (Harvey, 2015; Onwuegbuzie & Byers, 2014).  Fourth, researchers should 
conduct member checking to verify if their interpretations of participant responses are 
correct.  Fifth, a field journal can help decrease bias and personal lens influences (Yin, 
2014).  Researchers should keep a field journal (research diary) to record notes and 
account for thought processes during the study. 
My intent was to use an interview protocol (Appendix A) to conduct the 
interviews.  The researcher can enhance interview protocol reliability by ensuring the 
interview questions align with the research questions (Castillo-Montoya, 2016).  
Semistructured interviews permit the researcher to probe participants’ responses, which 
leads to a dynamic, deep inquiry of phenomenon based on the participants’ responses 
(Brinkmann, 2014; McIntosh & Morse, 2015; Mojtahed, Nunes, Martins, & Peng, 2014).  
I derived the semistructured interview questions based on the research question and 
conceptual framework, BPM.  An interview protocol serves as a procedural guide, 
including the start-to-finish script for the entire interview process (Jacob & Furgerson, 
2012).  The interview protocol assisted me to reiterate the research objectives, 
standardize the interview process, reduce variability, and mitigate bias.  
Participants 
Participant eligibility criteria define the study population.  To address the 
overarching research question, I recruited successful VC’s who previously evaluated LS 
management teams’ drug development capabilities as part of their investment process.  
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Study participants must have experience with the phenomenon and be willing to provide 
information for addressing the research question (Cleary, Horsfall, & Hayter, 2014; 
Robinson, 2014; Yin, 2014).  The study inclusion criteria were 10 VC partners and 
managing directors from venture capital firms located across the United States and 
Canada who have expertise in evaluating LS management teams.  The National 
Association of Securities Dealers Automated Quotations (NASDAQ) and the New York 
Stock Exchange (NYSE) website contained listing of all LS IPO firms within the past ten 
years.  The IPO listing represents a successful investment exit (Ogura, 2017; Sahaym, 
Cho, Kim, & Mousa, 2016).  Investment success, as evidenced by reaching an IPO or an 
M&A, is a relevant aspect of the research question.  
The study exclusion criteria included VC partners or managing directors solely 
financed by corporate or government venture capital firms.  Successful exits are not the 
primary motivations of corporate venture capital and government venture capital firms 
(Brander, Du, & Hellmann, 2014; Chemmanur, Loutskina, & Tian, 2014).  Although 
venture capital firm employees, such as analysts, play important roles in the selection 
process, they are not the final investment decision makers (Feld & Mendelson, 2014; 
Ramsinghani, 2014).  Consequently, I excluded analysts or research associates employed 
in the venture capital firms.  These inclusion and exclusion criteria demonstrate 
alignment with the overarching research question because this participant profile has 
successfully evaluated LS management teams’ drug development capabilities.  
Gaining access to elite research participants such as VCs was challenging.  
Accessing any participants’ knowledge and experience requires the researcher to build a 
59 
 
respectful, open, and trusting partnership (Kondowe & Booyens, 2014).  Verbal, written, 
and electronic invitations are acceptable ways to contact the participant and solicit 
participation in the process (Yin, 2014).  My strategy for finding eligible VCs was to a) 
compile a list of Canadian biotechnology firms who reached an exit in the past 10 years; 
b) search the Canadian portfolio firms’ website (e.g., press releases or annual reports) to 
verify if a venture capital firm invested in the company; and c) visit the venture capital 
firm’s website.  As all participants were unknown to me, I e-mailed and telephoned 
prospective VC participants using contact information from their company website or 
LinkedIn.  The e-mail content included an invitation to participate and the attached IRB 
approved informed consent form.   
If the prospective participant did not respond to the e-mail inquiry within two 
business days, I sent a follow-up e-mail and telephoned the participant.  Telephone 
solicitation assists researchers in achieving recruitment goals (Foss, Kjærgaard, 
Stensballe, & Greisen, 2016).  My intent was to remove the participant from 
consideration if there was no response in 5 days following the final e-mail contact or 
voice message.  All 10 interviews were completed within 3 weeks following IRB 
approval and took between 22 and 75 minutes with a mean interview time of 60 minutes.  
My intent was to build a working relationship with the VCs from the onset.  
Outlining the researcher’s roles and responsibilities, the research objectives (Robinson, 
2014), and establishing transparency help build a trusting working relationship (Byrne, 
Brugha, Clarke, Lavelle, & McGarvey (2015).  In my introductory e-mail, I established 
trust and openness by introducing myself, the research objectives, the interview timelines, 
60 
 
the interview questions, and the IRB approved informed consent form.  We exchanged 
contact information and availability.  Accommodating study participants’ schedules and 
meeting location preferences increases willingness to participate and builds goodwill 
(Newington & Metcalfe, 2014).  Researchers should conduct telephone interviews at a 
time convenient for the participants and should not solicit more time than necessary. 
Research Method and Design  
The study involved exploring successful strategies used by some VCs to improve 
their evaluation processes of LS management teams’ drug development capabilities.  I 
employed a qualitative research method and case study design to conduct the study.  The 
following subsections include an explanation of the selected research method and 
research design.  
Research Method 
In this study, I used a qualitative research method.  Qualitative research is a 
comprehensive exploration of a social phenomenon (Park & Park, 2016) from the 
participant’s perspective (Hammarberg, Kirkman, & de Lacey, 2016).  The main aim of 
qualitative research is to use what, how, or why questions to generate descriptive (i.e., 
nonstatistical) insights into a problem (McCusker & Gunaydin, 2015).  Objective 
observation, thick-rich data collection from in-depth interviews, and reflection and 
analysis of texts and documents help the researcher understand the fundamental drivers 
and motivations behind actions (Kozleski, 2017). 
Quantitative research is a positivist approach to testing relationships between 
variables and measuring hypothesis (Choy, 2014).  Researchers use statistical analysis to 
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analyze and interpret information collected from a sample to draw conclusions about a 
wider population (Barnham, 2015).  Sample size, randomization, stratification, p-values, 
and confidence intervals affect the significance of the results (Simpson & Lord, 2015).  In 
sum, quantitative methodologists interpret factual data.  Consequently, a quantitative 
research method was inappropriate for exploring the meaning and social context of VC 
evaluation processes. 
Mixed method research integrates qualitative and quantitative research methods 
for an inquiry into a phenomenon (Maxwell, 2016).  Researchers may employ the two 
methods in parallel or sequentially in a research study (van Griensven, Moore, & Hall, 
2014). Merging qualitative and quantitative methods in one study could mitigate 
limitations of each method and provide richer insight into the phenomenon (Turner, 
Cardinal, & Burton, 2017).  The additional time and complexity deemed mixed methods 
research unsuitable for addressing the research question. 
The research question determines the research methodology.  Exploring strategies 
VCs used to evaluate LS management teams requires an inductive and constructivist 
perspective.  VCs decisions evolve from their unique values, beliefs, past experiences and 
firms’ objectives (Dhochak & Sharma, 2016).  The in-depth individualistic inquiry 
characteristic of qualitative research allows for deep insights into human behavior 
(Isaacs, 2014).  Consequently, I chose a qualitative research method. 
Research Design 
I used a multicase study design to collect information from a purposeful sample of 
10 VCs located in the United States and Canada.  Case study designs permit the 
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researcher to interact with participants in their environments (Tetnowski, 2015).  A 
multicase study approach allows the researcher to compare, contrast, and consolidate 
participants’ responses to similar lines of questioning (Leonard, 2014) and generate 
themes (Hyett, Kenny, & Dickson-Swift, 2014).  My selection for investigating and 
determining themes from several VCs perspectives was the multiple case study design. 
Other research designs for exploring a research question include ethnography, 
phenomenology, grounded theory and narrative studies.  Ethnographic researchers focus 
on collecting information about a phenomenon through observation or examination of 
people over an extended period (Segelström & Holmlid, 2015).  The ethnographic design 
allows the researcher to observe participants in their environment but does not permit her 
to offer suggestions or behavior modifications (Ross, Rogers, & Duff, 2016).  I required 
VCs to articulate their past investment experiences and observing them in their present 
setting would not address the research question. 
In a narrative approach, researchers listen to participant stories about their lives or 
events and organizes it into a chronological order (Rooney, Lawlor, & Rohan, 2016).  
The emphasis of my study was to explore VC strategies used to evaluate management 
teams and listening to broad stories about VCs’ lives, or their investments could derail 
the research study.  Phenomenologists seek to understand a phenomenon based on the 
meaning and reflections participants attach to their lived experiences (Sohn, Thomas, 
Greenberg, & Pollio, 2017).  Grounded theorists develop a theoretical framework from 
several iterations of data collection (Lowe, Milligan, Watanabe, & Brearley, 2015).  
None of these approaches were appropriate for the present study.   
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Knowing when to stop data collection is a challenge for qualitative researchers.  
Data saturation occurs when additional data collection contributes no new themes or 
ideas to the research study (Gentles, Charles, Ploeg, & McKibbon, 2015).  The data 
collection methods (e.g., interviews), sample size, and sample selection determine when 
data saturation is reached (Fusch & Ness, 2015).  VCs who assessed a LS firm for 
investment which have successfully reached an IPO or M&A exit are a niche group.  A 
study will require fewer participants if the research question addresses a niche group and 
the researcher engages in strong in-depth dialogue during the data collection process 
(Malterud, Siersma, & Guassora, 2016).   
In-depth qualitative research inquiry into even a single case can yield valuable 
insights (Boddy, 2016).  Further, two or three case studies could be sufficient for 
exploring a phenomenon within a homogenous population (Yin, 2014).  The sample for 
this study included 10 VCs from venture capital firms in the United States and Canada.  
My intent was to code and analyze the interview data using software.  Interviewing 
several participants from more than one venture capital firm to gain an understanding of 
how VCs improve their evaluation processes of LS management teams made using a case 
study design appropriate.  The multiple case study design provided sufficient data 
saturation to help develop a detailed account of the investment improvement 
phenomenon.  When no new major themes emerged from the interview data, I concluded 
the data was saturated. 
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Population and Sampling  
Researchers must select an appropriate and representative sample from the 
population (Robinson, 2014).  The research question for this study is what strategies 
successful VC partners used to improve their evaluation processes of LS management 
teams’ drug development capabilities.  The study population to answer this question 
included data from 10 VCs from 10 separate companies who successfully invested in a 
LS firm in the last 10 years.  The participants of this study were residents of the United 
States or Canada.  The participants had professional experience evaluating LS 
management teams’ drug development capabilities, demonstrating alignment with the 
research question.  
I selected the participants using purposeful sampling.  In a purposeful sampling 
strategy, participants are selected because they have experience with the phenomenon and 
can provide in-depth information about a phenomenon (Duan, Bhaumik, Palinkas, & 
Hoagwood, 2015; Palinkas et al., 2016).  Homogeneous populations can also reduce 
variation and simplify data analysis (Duan, Bhaumik, Palinkas, & Hoagwood, 2015).  
Two or three case studies could be sufficient for detailed investigation of a phenomenon 
within a homogenous population (Yin, 2014).  Galvin (2015) asserted that if a theme is 
present in 25% of the overall subject population, then there is at least a 76% chance the 
theme will emerge in an interview of five participants.  I interviewed 10 participants and 
achieved data saturation after five interviews to yield the major themes. 
Data saturation affects the transparency and credibility of qualitative research. 
Data saturation occurs when participants provide repetitive responses to interview 
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questions or when no new themes or codes emerge (Gentles et al., 2015).  Five 
participants in a case study are sufficient to provide thick, rich data in a homogenous 
population (Molenberghs et al., 2014; Yin, 2014).  Engaging in in-depth inquiry with a 
niche group of 10 VCs who invested in LS firms which reached an IPO or M&A exit was 
sufficient for data saturation.  If I did not achieve data saturation by interviewing at least 
five VCs from venture capital firms in the United States and Canada, my intent was to 
continue interviewing additional VCs until data saturation. 
Participant selection criteria must be appropriate to the study.  Appropriate case 
study participants possess expertise, experience, knowledge, and a willingness to share 
their ideas (Bardus, Blake, Lloyd, & Suggs, 2014; Brooks & Normore, 2015; Thompson, 
Petty, & Scholes, 2014).  Participants must be (a) a partner or managing director level VC 
within a U.S. or Canadian venture capital firm, (b) available and willing for interviewing 
via telephone, and (c) 18 years or older.  Canadian biotechnology or major 
pharmaceuticals IPO listings are available on the NASDAQ and NYSE websites.  I 
reviewed the Canadian biotechnology IPO firms’ websites to investigate if a venture 
capital firm financed them.  If the venture capital firm invested in the IPO firm, typically 
the venture capital company website listed the VC’s contact information.  Additionally, I 
scanned the CVCA and NVCA websites for a listing of VC firms that invest in LS 
companies. 
I requested study participants to respond to semistructured interviews questions 
via telephone.  The open-ended question format permits the researcher to probe 
participant responses, adding flexibility to the format (McIntosh & Morse, 2015).  The 
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semistructured interview questions improve reliability, help direct the conversation, and 
encourages further dialogue (Jamshed, 2014).  Telephone interviews are often more 
comfortable and convenient for participants (Saura & Balsas, 2014).  When a researcher 
develops rapport and communicates respect for the participant, a telephone interview 
format is amenable to thick-rich data collection (Drabble, Trocki, Salcedo, Walker, & 
Korcha, 2016; Yin, 2014). 
Ethical Research 
Researchers involving human subjects in their study must ensure the research 
protocol, the informed consent form, and any other documents provided to the 
participants are approved by an IRB or institutional review board (Blackwood et al., 
2015).  I obtained ethics approval from Walden University’s IRB (IRB approval number 
11-03-17-0639637) before conducting any study related procedures.  My intent was to 
safeguard the well being and safety of my interviewees at all times during the study.   
After receiving Walden University IRB approval to conduct this study, I 
communicated with study participants as follows: 
1. I e-mailed the VC to request participation, described the purpose of this study, 
reminded the VC about voluntary participation, and informed the VC about his right 
to end the interview at any time. 
2. I advised the VC he is free to refrain from answering any questions he feels 
uncomfortable about. 
3. I explained to each VC the identity protection and confidentiality method I 
will use prior to conducting the interview. 
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4. I requested the VC to review the Informed Consent Form to ensure his 
understanding of this study purpose and my role in this study. 
5. I conducted interviews after IRB approval and after the participants’ provided 
Informed Consent (see Appendix B) by replying to an email with “I consent”. 
6. On the day of the interview, I followed the interview protocol (see Appendix 
A).  The interview protocol outlined steps for ensuring standardized execution of the 
interviews.  
The Informed Consent Form is a vital document to protect and inform human 
participants about the research study.  Transparency and clarity are important elements of 
the informed consent process (Atz, Sade, & Williams, 2014).  The informed consent 
process requires the researcher to explain the nature of the study to the participant, 
answer any questions, and allow the participant time to reflect before signing (Gainotti et 
al., 2016).  A predominant ethical consideration is protecting the privacy and 
confidentiality of study participants (Mealer & Jones, 2014).  Participants had an 
opportunity to ask me questions about the study via telephone or e-mail.  The informed 
consent form for the present study included the purpose of the study, study procedures, 
the voluntary nature of participation, risks and benefits, a privacy statement, contact 
information, and sample interview questions. 
 Researchers should make efforts to be sensitive to participants and their requests.  
To build rapport with the participants of the research study, I conducted the interview 
during a mutually convenient time via telephone.  Researchers should not coerce 
participants nor offer incentives for involvement.  Participants had the opportunity to 
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withdraw without penalty at any time during the study.  If a participant withdraws 
consent after the interview, my intent is to expeditiously shred and destroy data provided 
by the participant.  
Specific measures to ensure the ethical protection of participants included using 
participant deidentification codes instead of names and appropriate labeling of hard-copy 
and electronic data.  I deidentified participant names, organization names and specific 
investment history during the data collection, analysis, and reporting stages with codes.  
My intent is to protect source documents (including paper and USB drives) for 5 years in 
a locked safe, after which I will permanently destroy the files. 
Data Collection Instruments  
I served as the data collection instrument for this study.  My intent was to prepare 
the semistructured interview questions, conduct the interviews, transcribe the interviews, 
and analyze and report the data.  Semistructured interviews are organized around a set of 
predetermined questions which permit other questions to emerge from the discussion 
(Palinkas et al., 2016).  Using open ended questions (see Appendix A) with research 
participants, I collected and recorded information about how VCs have improved their 
evaluation processes of LS management teams’ drug development capabilities.  
Rigor is an important consideration in qualitative research.  Researchers can 
potentially introduce bias into qualitative research from their personal characteristics 
(e.g., gender, culture, or education) and their past experiences (Chenail, 2011).  Using a 
software program to code and analyze the data helped minimize bias.  Telephone 
interviews may provoke more clarification questions from interviewees (Irvine, Drew, & 
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Sainsbury, 2013).  I spoke clearly and clarified any questions when asked.  Further, I 
conducted the telephone interviews from my home office to ensure privacy.  
Researchers must triangulate several sources to enhance the reliability and 
validity of the data.  Data triangulation is a process where several data sources are 
checked for similarities, discrepancies, and for verification of events or statements 
(Carter, Bryant-Lukosius, DiCenso, Blythe, & Neville, 2014).  I reviewed company 
websites (venture capital and LS firms), financial reports, and press releases to triangulate 
data.  Member checking is a process used for ensuring the accuracy of the collected data 
or the researcher’s interpretation of the data (Harvey, 2015).  Postinterview, participants 
reviewed my interpretive summaries for verification and confirmation of accuracy.  
Data Collection Technique 
The research question for this study is what strategies do successful venture 
capital partners use to improve their evaluation processes of LS managements teams’ 
drug development capabilities.  I used several data sources to address the research 
question.  The sources included open-ended interviews, company documents, and press 
releases.  Before the interview, my intent was to contact each participant to schedule the 
telephone interview, discuss the informed consent form, address any questions, request a 
signed and dated informed consent form, and verify consent to record the interview.  
Following the preinterview contact, I conducted the interview on the prearranged 
date.  Researcher’s write protocols to explicitly document procedures, thus ensuring 
consistency, integrity, and accountability (Goto, Muragaki, & Aruga, 2016).  Significant 
protocol deviations may impact data collection and interpretation (Moher et al., 2015).  
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The Interview Protocol (see Appendix A) outlines the study conduct procedures from the 
beginning to the end of the interview.  The steps included greeting the participant, 
reviewing interview procedures (including audio recording), conducting the interview, 
reminding the participant about member checking, and closing the interview.  
I conducted all interviews via telephone, which ranged from 35 to 75 minutes.  
Telephone interviews allow participants flexibility to participate from their own social 
space (Redlich-Amirav & Higginbottom, 2014), such as their home or office.  Face-to-
face interviews may elicit social desirability bias, a situation where interviewees provide 
responses to appease the interviewer (Szolnoki & Hoffmann, 2013).  In-person interviews 
would be financially onerous for me because the VCs resided in a broad geographical 
area.  Skype video conferencing is an alternative for research interviews and brings an 
opportunity to observe the participant’s facial cues (Janghorban, Roudsari, & Taghipour, 
2014).  While Skype is an increasingly popular choice in interview techniques, video 
conferencing could be more prone to technical difficulties, and some participants might 
not have access to a webcam.  To maintain participant engagement and comfort, 
researchers should minimize study conduct difficulties (e.g., technical difficulties).  
Additionally, variations in interview mode (e.g., using both Skype and telephone 
modalities) could increase variability of responses, therefore, my intent was to solely use 
telephone interviews. 
Company annual reports (e.g., Form 10k and Form 10Q) and company websites 
are important data sources.  Yin (2014) asserted that a case study should have a minimum 
of two sources of evidence for data collection. Publicly available documentation such as 
71 
 
annual reports and websites are unobtrusive and corroborate information collected during 
the interviews (De Massis & Kotlar, 2014).  Requests for internal documents could 
increase participant apprehensiveness, discomfort, and privacy concerns (Henderson, 
2016).  While I did not review any proprietary checklists from the VCs for evaluating 
management teams during their due diligence process, the details of the checklists were 
discussed during the interviews.  Researchers should not anticipate permission to view 
confidential and highly sensitive internal records.  If granted access, my intent was to 
treat company documents as private and confidential data. 
 Post interview, I transcribed the interviews from the audio recordings into a 
Microsoft word document.  My intent was to summarize and interpret each interview 
transcript.  Member checking validates the response and interpretation accuracy (Birt, 
Scott, Cavers, Campbell, & Walter, 2016; Harvey, 2015; Onwuegbuzie & Byers, 2014).  
Study participants reviewed my transcript interpretations, to ensure accuracy and 
consistency of their verbal responses.  All participants were available for further data 
clarification as needed. 
Data Organization Technique  
Source document maintenance is vital in research studies.  Maintaining source 
documents which are legible, complete, and attributable can help an independent 
observer reconstruct the study and to confirm the data (Bargaje, 2011).  Good 
documentation practices also include recording every participant contact on a log 
(Weisskopf, Bucklar, & Blaser, 2014).  I kept a research diary, a master list of VCs, VC 
contact information, and venture capital firm locations in a file on a password protected 
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USB drive.  I assigned each VC a participant identification (ID) number, which will be a 
combination of an alphabetical and numerical file name.  Each participant file containedd 
e-mail correspondence, interviews’ recordings, and a record of any contact.   
An iPhone 7 smartphone and the TapeACall Pro™ app served as the recording 
instrument the for the interviews.  Subsequently, I uploaded the audio files to a USB 
drive as the master storage device. NVivo 11® will served as the software for coding and 
analyzing the raw data.  My intent is to store the USB key in a locked cabinet containing 
all study data for five years following Walden University CAO approval.  
Data Analysis  
Triangulation in case study research mitigates bias and increases the validity of a 
study.  According to Denzin (1970), there are four types of triangulation: data 
triangulation, investigator triangulation, methodological triangulation, and theory 
triangulation.  I used methodological triangulation in this study.  In trigonometry, 
triangulation is the process of identifying one’s position by measuring the person's angles 
to two other known positions (Joslin & Muller, 2016).  Triangulation in qualitative 
research is using two or more sources to achieve an in-depth understanding of a 
phenomenon (Denzin, 2012).  The combination of multiple sources adds rigor, breadth 
complexity, richness, and depth (Denzin, 1970).  
Data analysis is an involved and tactile component of qualitative research.  
Qualitative data analysis is organizing data into manageable parts and noting patterns and 
repetitions (Yin, 2014).  Open-ended questions, company documents, and press releases 
gathered during data collection and their subsequent analysis helped answer the research 
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question.  The original transcripts served as the basis for data analysis, and I assessed the 
entire transcript.  Qualitative data analysis can include inductive and deductive 
approaches (Graneheima, Lindgrena, & Lundman, 2017).  Inductive data analysis is 
categorizing raw data into themes through repeated comparisons for a more granular 
understanding of a phenomenon (Graneheima et al., 2017).  Deductive data analysis is the 
process of fitting the raw transcript data into the model’s or theory’s dimensions 
(Graneheima et al., 2017).  
Qualitative researchers distill and interpret themes from raw, unstructured data.  
Coding involves highlighting and subdividing textual data into salient categories and 
labeling these with code words (St.Pierre & Jackson, 2014).  Transcripts can have several 
succinct codes.  The codes are organized or grouped into interconnected broader themes 
and sub themes (Brinkmann, 2014).  I carefully read the transcripts several times and 
labelled sections of phrases.   
My intent was to use deductive coding to group the transcripts based on the 
interview questions (e.g., I reviewed Question 1 answers, Question 2 answers, and so on).  
Within each question grouping, my inductive analysis helped to code sections.  
Combining codes into similar groups and labelling these groups as themes helped me 
make connections and to link these themes to answer the research question. 
Researchers increasingly use computer software in qualitative data analysis.  
NVivo 11 Plus® is a computer software which enables researchers to systematically 
organize, and analyze several forms of raw textual data such as interviews, focus groups, 
websites, and other documents (Castleberry, 2014; Woods, Paulus, & Atkins, 2015).  
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Importantly, NVivo 11 Plus® assists the researcher’s analysis process but does not 
conduct data analysis for her (Zamawe, 2015).  NVivo 11 Plus® users can highlight 
sections of text and assign it to a priori “nodes” (Sotiriadou, Brouwers, & Le, 2014).  The 
themes can include categories and sub-categories (Sotiriadou et al., 2014).  I inputted my 
interview transcripts, and other data sources into my a priori and ad hoc nodes in NVivo 
11 Plus®.  Finally, my intent was to seek themes that aligned with the BPM conceptual 
framework. 
Transcription quality can impact data analysis.  Researchers may hire an external 
transcription service to transcribe the interviews.  Transcriptionists must comprehend the 
recording content to maintain dependability (Stuckey, 2014).  Even when researchers hire 
external transcriptionists, the researcher must review the audio recordings with the 
transcribed document to ensure accuracy.  To save resources researchers sometimes 
transcribe interviews themselves.  After uploading the audio files into NVivo 11 Plus®, I 
transcribed the interviews directly in the software. 
Reliability and Validity  
Reliability 
Reliability and dependability are a fundamental cornerstone of the qualitative 
research paradigm.  Trustworthiness helps evaluate rigor in qualitative research (Elo et 
al., 2014).  Triangulation, member checking (transcript review), and a study protocol 
increases data reliability in case study research (Cronin, 2014).  Triangulation is 
corroborating more than one source to strengthen evidence whereas a protocol helps 
assure consistency and reproducibility (Cronin, 2014).  Member checking helps to 
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validate qualitative research by reengaging the participants to verify the researcher’s 
interpretations with their intended meaning and word choice (Harvey, 2015; 
Onwuegbuzie & Byers, 2014).  Sending data interpretations and conclusions back to the 
participants for review is instrumental in enhancing reliability (Elo et al., 2014).  
My plan for increasing the reliability and dependability of this case study included 
using (a) multiple data collection sources (e.g., company documents, press releases, and 
conducting semistructured interviews), (b) conducting the study as outlined in the 
research protocol (see Appendix A), (c) conducting member checking, and (d) 
continuously inspecting the raw data and interview notes to verify the data.  Following a 
protocol will ensure procedural reliability and will decrease variations.  Researchers can 
achieve data consistency by documenting the process of inquiry (Baskarada, 2014; Cope, 
2014).  I took notes, allocated sufficient time for the interview, and recorded the 
interviews.  Sufficient time with participants can help build trust and engagement (Cope, 
2014).  After completing the interviews, participants reviewed my interpretations of the 
transcripts.  
Validity 
Credibility, transferability, and confirmability are used to determine the validity in 
a qualitative study (Noble & Smith, 2015).  Member-checking and triangulation are 
strategies to ensure data truthfulness, confirmability, and credibility (Noble & Smith, 
2015).  I selected a purposeful sample of VCs from the United States and Canada.  
Member checking is a review process for ensuring the accuracy of the collected data or 
the researcher’s interpretation of the data (Harvey, 2015).  Data triangulation is a process 
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where several data sources are checked for similarities, discrepancies, and for verification 
of events or statements (Carter et al., 2014).  My intent was to member-check, triangulate 
the data, and include selected participant quotes to demonstrate study credibility and 
confirmability.  
I do not expect to transfer or generalize the findings of this study to other 
contexts.  Qualitative researchers conduct inquiry into a selected population about a 
phenomenon (Leung, 2015).  Hence, the results of a qualitative study may not apply to 
other settings or groups.  The research question is specific to venture capital partners’ 
process improvement when evaluating LS management teams’ drug development 
capabilities, which is a niche group.  Other researchers must determine themselves if a 
qualitative study’s findings may apply to their circumstances (Marshall & Rossman, 
2016).   
A researcher must establish confirmability.  Qualitative researchers may include 
participant quotes which represent a theme to demonstrate confirmability (Cope, 2014).  
Quotes provide evidence that the study results are shaped by the participants and help 
illustrate reasons for producing specific themes.  I demonstrated confirmability by 
reviewing peer-reviewed literature and data triangulation to support the study results.  
Researchers must collect sufficient data to answer the research question and 
delineate criterion for data saturation.  Data saturation occurs when participants provide 
redundant responses to interview questions or when no new themes or ideas emerge 
(Gentles et al., 2015).  Purposeful sampling permits the researcher to sample a more 
homogenous sample to achieve data saturation with fewer participants (Fusch & Ness, 
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2015).  Researchers should justify their chosen sample to ensure study validity (Yin, 
2014).  My intent was to engage in in-depth inquiry with a niche group of VCs who 
assessed LS management teams and have successfully exited a deal via an IPO or M&A.  
Although my expectation was to achieve data saturation by interviewing five VCs from 
venture capital firms in the United States and Canada, I conducted 10 interviews.  I 
adhered to the study protocol (see Appendix A), interviewed until I reached data 
saturation, triangulated data sources, member checked, and meticulously analyzed the 
data for themes.  
Transition and Summary 
In Section 2, I described the research method and design, participants and 
population sampling, data collection and analysis techniques, and the study’s reliability 
and validity.  Data collected through interviewing and other sources 
supportedunderstanding and knowledge of VC evaluation processes of LS management 
teams’ drug development capabilities.  The identified themes have the potential to 
illuminate important information for VCs, LS management teams, scientific research 
constituents, and the investment community.  I intend for this qualitative study’s findings 
to be an impetus for further research into VC evaluation processes for LS management 
teams and other industries.  In Section 3, I present the major themes identified from the 
semi-structured interviews and coding process. 
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Section 3: Application to Professional Practice and Implications for Change  
Introduction  
The purpose of this qualitative multicase study was to explore strategies 
successful VCs use to improve their evaluation processes of LS management teams’ drug 
development capabilities.  I collected data from 10 VCs using semi-structured interviews 
and triangulated the information with annual reports and articles.  The emergent themes 
from the participants’ responses and documents reviewed revealed insights into strategies 
some VCs use to improve their evaluation processes of LS management teams’ drug 
development capabilities.  The following four themes emerged from the participants’ 
responses (a) begin with the exit in mind, (b) collapse learning timelines, (c) conduct 
systematic due diligence, and (d) cultivate and critique one’s drug development expertise.  
Presentation of the Findings  
Four themes emerged from the data analysis.  I organized the transcript data for 
analysis from 10 participant interviews.  The purpose of these interviews was to address 
the central research question: What strategies do successful VCs use to improve their 
evaluation processes of LS management teams’ drug development capabilities?  The 
funding stages were seed, early, expansion, and mezzanine. 
The population consisted of 10 participants from the United States and Canada. 
Six VCs resided in the United States and four VCs resided in Canada.  I contacted 44 
VCs in the both countries to request participation in the study.  The participant locations 
were skewed towards the Eastern Time Zone with six from the east coast and four 
participants were from the Pacific Standard Time Zone.  No participants resided in the 
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Mountain Standard Time Zone.  Nine VCs were male and one VC was female.  Although 
I invited other female VCs, they either were not interested in the study or did not have 
sufficient time to dedicate.  This variance may have influenced the findings of the study, 
however, because of the small number of participants and the qualitative nature of 
inquiry, specific subanalysis between the participant subpopulations was unsuitable. 
To protect participant confidentiality, I provided a broad overview of the 
participant sample.  The number of partners/managing directors differed among the 
represented firms.  One firm had two managing directors, and the remaining firms ranged 
from five to 11 partners or managing directors.  Some firms were solely dedicated to 
health care or LS investments and others had a combination of investments in LS, 
information technology, security, and clean energy.  Participant QR09 invested in over 
200 companies during his career.  Participant AB01 assessed approximately 1100 LS 
deals in his career.  Fund sizes ranged from 50 million to over 500 million USD and were 
LS-specific funds except in a few instances.  All participants achieved at minimum a 
Bachelor of Science degree, three held a Master of Business Administration degree, and 
five participants held a Master of Science degree.  Two participants held either a Doctor 
of Philosophy or Doctor of Medicine degree.  One participant achieved a Juris Doctor 
degree.  Participants’ experience evaluating LS management teams spanned from 4 to 30 
years.   
I assigned each participant an ID code.  Following the telephone interviews, 
which ranged from 22 to 67 minutes (see Table 2), I transcribed and coded the data to 
derive themes.  To preserve participant anonymity, I aggregated the data into themes to 
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identify the strategies successful VCs use to improve their evaluation processes of LS 
management teams’ drug development capabilities.  I triangulated the interview data with 
archival data such as company websites, and online articles.  Writing reflexive journal 
entries helped minimize researcher bias.  The following subsection outlines the emergent 
themes.  All themes tied to the BPM conceptual framework.  
Table 2 
Participant Interview Duration 













Life Science Management Team  
 The management team is the nucleus of the company.  The participants articulated 
several attributes they require their LS CEO and management teams to possess.  
Participant IJ05 summarized the sentiment with, “It doesn’t matter how much we love an 
asset.  If we cannot put in place the right management team, we will not make the 
investment.”  Others reported the time to exit moderated the emphasis placed on the 
management team.  Gerasymenko and Arthurs (2014) revealed that VCs particularly 
emphasized the importance of the management team if the projected time-to-IPO is long 
as opposed to a quick exit.  I grouped the participant’s responses into three main 
categories: character traits, management skills, and drug development specific skills.  
 Character traits.  The participants mentioned several desirable character traits.  
Most participants cited an entrepreneur’s coachability and flexibility as highly 
significant. Bryan, Tilcsik, and Zhu (2017) found that entrepreneurial teams with subject 
matter expertise were more resistant to outsider advice than less experienced teams.  
Considering many LS CEOs previously held clinician roles, Blanchard (2017) asserted 
that coachability, vulnerability, and self-awareness were pivotal attributes for physicians 
transitioning into leadership positions.  Participant QR09 stated: 
As long as the management team is open to the assistance that they need and 
recognizes what they know and don’t know, I think we’ll do what we can to help. 
We will help them find the right resources to match up with the product and the 
technology they are working on. 
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One participant cautioned entrepreneurs to avoid asking for assistance with trivial issues 
to make the best use of the VCs expertise.  Participant GH04 explained, “We’ve seen 
some CEOs ask almost too many questions where it shows a lack of confidence.  For 
example, some individuals asked me, “Here are three designs of my business card, which 
do you think is the best?”  All participants cited some variation of the terms honesty, 
transparency, integrity, humility, and ethical as important character traits.  Cormier, 
Lapointe-Antunes, and Magnan (2016) conveyed that CEO hubris was an antecedent to 
financial malfeasance even in the presence of strong boards.  Participant AB01 
emphasized, “Though we are just the money or maybe even smart money, a VC cares 
that the entrepreneur honors that.”  A CEOs character may also lead to future deals.  
Participant QR09 added, “Believe it or not, I have had investments in companies that 
were total failures, and I wouldn’t hesitate to invest in the CEO again because they were 
transparent, honest, and effective.”  
 Management skills.  A leading management skill which the VCs required from 
the LS management team and the CEO was a competitive mindset.  The participants 
searched for management teams with the foresight to build an economic moat around 
their assets and platform offering.  Chollet, Géraudel, Khedhaouria, and Mothe (2016) 
advised that a CEOs curiosity and openness is directly related to the level of competitive 
knowledge she seeks.  Participant AB01 specified: 
Because often times when you ask an entrepreneur who is your competition? 
What are other people doing?  It is very rare to get a complete and honest 
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assessment. And that’s really telling for you as an investor.  If an entrepreneur 
says we have no competition, the conversation is over.   
Another frequently cited skill was the CEOs ability to build a senior leadership team with 
complementary skills.  The best CEOs surrounded themselves with other talented 
executives, investors, and advisors.  Strong management teams expanded their spheres of 
influence to increase the likelihood of success.  Chatterjee and Pollock (2017) proposed 
that narcissistic leaders construct senior management teams with less experienced 
members who lack confidence or fear challenging authority.  Participant IJ05 suggested: 
There are certain skills regardless of the investment stage that if existing 
managers do not have them, I don’t think those are skills they can acquire in a 
short period of time.  So we would rather think about either replacing those 
individuals or complement the teams with new folks that have the right skills.   
Other management skills the participants mentioned were communication, maintaining 
high standards, short and long-range planning, and visionary thinking.  In general, 
participants did not elaborate on metrics or how they measured skills in prospective 
management teams.  Participant GH04 summarized, “There are some things we can 
easily measure, but especially when it comes to management teams, there is so much that 
we have no idea how to measure.” 
Drug development skills.  Skills specific to drug development which the 
participants noted were scientific expertise, financial acumen, well-informed about the 
drug development process (e.g., regulatory, reimbursement, manufacturing, 
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commercialization, patenting, and clinical trials), sector knowledge, and fundraising 
savviness.  As previously cited, Gompers et al. (2016) found VCs working with health 
care/biotechnology firms rated the management team’s industry experience as most 
important.  While the participants preferred the management teams with previous drug 
development experience, strong scientific knowledge with a willingness to learn the other 
aspects was received positively.  Participant KL06 surmised: 
No one person has every skill.  So you want a CEO who is a good integrator of all 
of the different kinds of skills, who is able to create and tell a story to investors 
and pharmaceutical companies, who has some relationships in investment 
banking, and hopefully some experience in drug development. 
Remarkably, only one participant stated a preference for management teams who are 
committed to treating patients and with a vision to improve society.  
Theme 1: Begin with the Exit in Mind 
The first emergent theme involved beginning with the exit in mind.  Successful 
VCs connected every decision to the exit potential, including the valuation, timelines, and 
exit route.  Correspondingly, Gerasymenko and Arthurs (2015) discovered that VCs 
made early forecasts about the exit type and time-to-exit from their investments.  As 
participant MN07 noted, “The minute I meet an entrepreneur I start to think about the 
exit.  The best investors will always have that top of mind.”  When participants assessed 
the market dynamics for an asset, they initially consider the number of years before they 
must harvest, because the number of years remaining in the fund determines the LS 
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company stage they could reasonably consider investing in.  For instance, VCs with a 
fund due for harvesting in 2 years would not invest in a seed-stage LS company.  
However, a VC managing a fund with 8 to 10 years remaining until harvest may consider 
investing in a seed-stage LS company.  Bock and Schmidt (2015) suggested that first 
time VC funds maintained their shares longer post IPO lockup period than other funds 
with satisfactory performance.  The participants analyzed variables such as the 
investment funds required for drug development, the market dynamics, asset 
differentiation, and whether the current management team could potentially lead the 
company to an acquisition or an IPO.  VCs also devised potential scenarios and 
calculated the probability of occurrence.  Participant QR09 noted, “We expect companies 
to miss milestones.  That is a reality of developing a product in a new company that the 
milestones are often missed.  We expect a plan in place for what to do in case milestones 
are missed.”  
 Eight of the interviewees (78%) mentioned the fiduciary responsibility to the 
limited partners.  Participant AB01 offered, “Your job as a VC is as a steward of other 
people’s money.  Your job is to return the most that you can in the specific period that 
your fund operates.”  Participant GH04 asks the question, “If I take my LPs money and I 
put it in the hands of this person, will they be able to multiply it?”  Recently, Jia and 
Wang (2017) found increased capital commitment from the general partner was 
correlated with improved exit success.  The participants further evaluated potential deals 
based on the alignment with the fund strategy.  For instance, some portfolios required a 
percentage of regional investments.  Additionally, some participants focused on LS 
86 
 
companies who were developing treatments in certain therapy areas, such as oncology or 
rare diseases.  Some researchers warned that narrow investment strategies may hinder 
investment returns.  Buchner, Mohamed, and Schwienbacher (2017) informed that skilled 
VCs who invested in diversified industries and different stages of companies earned 
higher returns than non-diversified portfolios.   
 Every participant (100%) had substantially more M&A exits in their LS 
investments than IPO exits.  This finding supports Moustakbal (2014), who reported that 
venture-backed Canadian biotechnology firms had an increased probability of an 
acquisition than IPO.  Participant KL06 suggested: 
The best IPO candidate is often the best M&A candidate.  They have options.  
They can go many ways.  They can say no the first time if it’s not the right offer 
and raise more money in the public exchange and wait a bit.   
Participants discussed the complexities accompanying an IPO in LS companies, such as 
the ideal timing based on available clinical trial data, investors required for mezzanine 
financing rounds, governance, accounting standards to withstand public scrutiny, and the 
ideal management team and board to go public.  Participant IJ 05 advised, “Plan for the 
right management team at the right time.”  Although no participant discussed 
management gender diversity, Quintana-García and Benavides-Velasco (2016) 
demonstrated that investors did not perceive that the presence of female senior managers 
enhanced IPO success for biotechnology firms in the United States,  
The participants also perceived that the risk and investment amount increased 
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directly with later stage trials.  Acquiring nascent biotechnology companies is an R&D 
and growth strategy for large biopharmaceutical companies.  Gilead Sciences Inc. 
acquired biotechnology companies such as Kite Pharma, Nimbus Apollo, and 
Pharmasset, all of whom had assets in early development, and no marketed products 
(Micklus & Muntner, 2017; Rosenmayr-Templeton, 2017).  Participant OP08 revealed: 
The risk is higher in Phase 3 trials.  So what you’d like to do is get out of that 
business before your money is at risk in a Phase 3 trial.  What I think works best 
was in terms of making money and never producing a single therapy out of the 
whole deal was getting to a place where you can sell the company.  Sell the 
company to GSK or Merck in the development stages and let them pay for the 
later stage trials.  
To illustrate, after acquiring YM Biosciences’s (lead product candidate momelotinib) for 
$510 000 000 in 2012, Gilead Sciences terminated the development of momelotinib for 
the treatment of myelofibrosis in 2016 following the failure of two Phase 3 studies 
(Gilead Sciences Inc, 2017).  Gilead eventually listed the investment as an impairment 
charge in their 2017 SEC Form 10-K filing.  
 BPM is about improving entire sequences of events, activities and decisions that 
help an organization reach its goals.  The VCs main objective is to deliver positive 
returns to their LP investors.  Therefore, VCs keeping potential acquisition or IPO central 
to their investment decisions (including evaluating LS management teams) serves as a 
harbinger for subsequent actions that are aligned to their firm’s objectives.  Participant 
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GH04 summarized cogently: 
We try to map it out. If we board this ship, we will be on board for 3 years or 8 
years or somewhere in-between.  Being aware that if I’m heading north, do I stop 
at Vancouver, Seattle, or Northern California?  How much gas do I need to get 
there?  What will my exit look like?    
Theme 2: Collapse Learning Timelines  
Participants also emphasized that they could collapse their learning timelines by 
learning from their own experiences combined with a keen alertness to the experiences of 
other investors.  This finding supports Harrison, Mason, and Smith’s (2015) assertion that 
learning from one’s experiences (e.g., failures) and from other investors in the syndicate 
helps investors streamline the due diligence process.  Participant MN07 explained, “I’m 
more thorough than I used to be.  I talk to more people.”  Increased communication and 
information sharing increases the collective knowledge bank and helps mitigate risk.  
Hora and Klassen (2013) demonstrated that firms leverage learning from others’ 
mistakes, especially when they have similar operations.  Experience correlates with better 
portfolio returns because investors are less affected by overconfidence behaviors 
(Koestner, Loos, Meyer, & Hackethal, 2017).  Participant QR09 quipped, “Having lived 
through failures and in some cases late failures of these kinds of technologies, it is too 
much money that has to be spent on drug development to go down the path of something 
that can’t be reproduced.”  Swank and Visser (2015) cautioned people to consider the 
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reputation of the information source and the verifiability of information before 
implementation.    
 Five participants (50%) discussed instances of nepotism in the LS management 
teams that were discovered either pre-or postinvestment and led to future process 
changes.  One participant suspected nepotism when a staff member’s salary was 
misaligned with a seemingly nebulous job title.  Participant GH04 reminisced: 
The CEOs spouse earned $350,000 per year for a soft job titled Chief Culture 
Officer.  What does that mean?  I mean, I’d love to be a Chief Culture Officer for 
$350,000, put my feet up and paint my toe nails all day.  And say, hey, is the 
culture ok today?  Good.  Let’s go home now.  Let’s make sure culture is good 
tomorrow. 
Participant AB01 discovered a CEO withholding information about his marriage to a 
generously compensated staff member before signing the term sheet.  He mused, “We 
were lucky though to pick up on that, and that was the reason we did not invest.”  The 
possibility of misalignment led to investor wariness.  Similarly, Parise, Leone, and 
Sommavilla (2016) observed that the existence of family or personal relationship ties in a 
management team deters external investors.  Participant AB01 further added, “We felt 
that if the guy couldn’t be honest about that [the personal relationship], what else was he 
going to be dishonest with when it was our money on the line?”  Participant IJ05 
expressed his disapproval about discovering nepotism post investment: 
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We didn’t realize we missed this.  The two were in a personal relationship, and 
that impacted the performance of the company so we thought that we should 
include the question from now on when we are assessing teams.  It’s a very 
sensitive issue obviously, but we should look at that.  And technically, if we have 
for example a husband and wife, people who are in a relationship in senior 
management of a LS company, we tend to be a little more cautious. 
Participant GH04 acknowledged that CEOs prefer to hire people they know and have 
relationships with.  He added, “The question remains, how does the entrepreneur remain 
accountable?  Is he willing to fire this person if something goes wrong?”  While soliciting 
peers for information was often useful, the three participants explicitly mentioned the 
importance of critical, analytical, and independent thinking skills.  A trust but verify 
approach.  Participant AB01 elaborated: 
The management team came highly recommended by another group that we held 
in high esteem.  We said, “oh that’s great, you have done the diligence, that’s 
fine.”  Then we found out later that they didn’t do the diligence and that their 
processes were significantly less vigorous than ours. 
 Behavioural science researchers suggest cognitive and emotional biases can 
supplant logical investment behavior (Pompian, 2016).  For instance, Joel, Plaks, and 
MacDonald (2017) elucidated that individuals fear missed romantic opportunities 
significantly more than the possibility of rejection.  Six participants (60%) revealed that 
examining and sometimes lamenting over lost investment opportunities (especially those 
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which were subsequently successful) encouraged them to fine tune their radars for future 
deals.  In his effort to learn from others, Participant AB01 discerned, “Did we miss any? 
Were there good deals that we missed on when we should have invested, and we just 
didn’t see what others saw.  And they had great success. Just rather out of knowledge, not 
envy.”  Several scholars (Lad & Tailor, 2016; Pompian, 2016) advised confirmation bias 
occurs when investors actively seek information that confirms their claims while 
minimizing opposing evidence.  The data shows that successful VCs counteract 
confirmation bias tendencies and stress test their assumptions.  Likewise, the BPM 
discipline is about enhancing actions which produce business outcomes to support a 
business strategy.  VCs who assiduously and routinely review their processes after new 
investment experiences are better positioned to support their firms’ objectives. 
Theme 3: Conduct Systematic Due Diligence 
All participants underscored the importance of performing rigorous background 
checks on prospective LS management teams before investments.  Participant GH04 
conveyed:  
My peers almost compare this to dating.  Everyone is always on their best 
behavior.  Their clothes are the finest.  They talk about the beautiful music they 
listen to, the great books they’ve read.  And then you of course two years down 
the road you ask…how did I end up in this relationship?”   
Cumming and Zambelli (2017) deduced that an exhaustive due diligence process 
conducted internally by fund managers is associated with better portfolio firm 
performance.  The participants mentioned several forms of due diligence, as confirmed in 
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recent studies (Cole & Lysiak, 2017; Cumming & Zambelli, 2017).  Background checks 
included reference checks, criminal records, third-party vetting, internet searches, 
LinkedIn, conversations with the management teams’ colleagues, peers, past and current 
investors, credit scores, and previous business dealings.  The length of the due diligence 
process ranged from 2 weeks to 1 year.  Participant KL06 stated, “We track people for a 
very long time.  It is very rare for us to invest in an unknown company where they make 
their pitch, and we invest two months later.  It is very rare.”  Similarly, participant GH04 
expressed, “there is a company we just passed on for a 20 million USD investment.  I 
think we must have spent collectively at least 250 hours between five of us looking at 
different aspects.”  
Venture capital investment increases interest from other investors.  Ogura (2016) 
confirmed how venture capital presence served as a certification signal for other 
investors.  Participant AB01 added, “By and large, the best sources of investment 
opportunities, particularly in LS come from other investment professionals, whether it is 
fellow investors, VCs, corporate strategic investors, or the lawyers that sponsor them.”  
 Eight participants (80%) used some variant of a checklist during the due diligence 
process.  One firm developed a 20-page due diligence checklist that included items such 
as market evaluation, the asset, the company, and the management team.  Soenksen and 
Yazdi (2017) developed a LS due diligence checklist which included items such as 
clinical and epidemiology data, technology and concept, market assessment, intellectual 
property, regulatory strategy, financing, business plan, risks and mitigation, and overall 
“gut feel”.  Checklists forced the VCs to follow a systematic vetting process and to 
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streamline their processes.  Participant IJ05 offered, “We have a general template or 
makeshift system which we qualify every opportunity according to.  And obviously, the 
management team has the highest ranking in that particular template.”  VCs always 
conducted some form of due diligence even if they entered the syndicate in later funding 
rounds.  Participant MN07 explained: 
Sometimes we co-lead deals so we share the due diligence workload.  Sometimes 
we’ll come later in the game and we would review parts of the due diligence that 
were done by the other investors.  But we will always do some due diligence.  
Even if we’re late in the game, the management piece will be done whatever the 
investment.  That’s the most important part.  
 Six participants (60%) requested prospective management teams to take 
psychometric tests.  Participant QR09 reflected, “One of the things we’ve learned over 
the years is as with anything, you’re dealing with human frailty, emotions, biases, 
whether they are intentional or not.”  The participants used the psychometric tests to 
determine behavioral patterns and to assess the psychological compatibility with the LS 
management teams.  For instance, Gemmell (2017) argued entrepreneurs with an active 
experiential learning orientation were more successful than reflective entrepreneurs.  
Arráiz, Bruhn, and Stucchi (2016) determined that secondary psychometric testing 




When it’s time to seek [sic] for an investment, people are always on their best 
behaviour.  It is really when the times get tougher that real behaviors start to 
emerge.  Sometimes under a lot of stress or pressure, the negative behavior will 
emerge, so we have to be careful. 
A BPM model informs an entire organization how a procedure is completed and how is it 
completed correctly every time.  VCs who follow systematic due diligence processes 
serve their firms by eliminating redundancies, minimizing errors, and minimizing bias to 
ensure they make sound investment decisions.   
Theme 4: Cultivate and Critique One’s Drug Development Expertise 
 The business of developing and commercializing a drug is a highly technical, 
costly, and complex process.  The most successful VCs cultivated their know-how about 
the intricacies of drug development such as the development of the pre-clinical and 
clinical data package, drug reimbursement, expanding their networks in the LS clusters, 
and positioning the portfolio company for a successful exit.  Participant QR09 
summarized: 
It’s a continuous improvement process.  I spoke with our board chairman last 
night.  I told him if people are of the belief that if it isn’t broke, don’t fix it, they 
probably do not belong in our organization.  And so, everything we do is open to 
reinterpretation to improvement, to process improvement.  We have to, because 
none of these businesses are stagnant (at least they shouldn’t be) and so we have 
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to work to continually refine and make the processes more relevant, more 
germane to decision making.  
The outcome that a VCs investing competence improves over time based on their 
commitment to continuous improvement contradicts other published studies.  Nanda et al. 
(2017) argued that a while a VCs initial success predicts his long-term investment 
success, overall, VCs were no better at discriminating investments than chance.  Further, 
more experienced VCs modified their investment strategies to later stage deals and to 
syndicated investments (Nanda et al., 2017).  This finding implies if a VC has successes 
early in his career, future deals will further reinforce his early success.  Marquez, Nanda, 
and Yavuz (2014) contended that high potential entrepreneurs seek out successful VCs 
based on their past performance.  The returns arising from venture capital funds are 
affected by numerous internal factors such as the fund amount, the fund lifespan, the 
managing VCs and associates, the quality of the portfolio company, and external factors 
such as the fund sector and the economy.  Consequently, researchers may encounter 
endogeneity problems when determining whether a VCs expertise is causally related or 
only correlated to investment success.  A theoretical solution to this problem is to 
conduct a longitudinal prospective study following a statistically robust sample of VCs 
who invest in LS companies.  Invariably, researchers would likely encounter difficulty 
finding VCs who agree to the aforementioned study. 
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 All participants emphasized that there is no substitute or checklist to replace 
experience in evaluating LS management teams.  Participant KL06 spends a considerable 
amount of time with several CEOs and keeps close contact.  He further added: 
In some cases, we know the person may not have scored the highest but there is a 
good reason to keep him in the running.  All of these things (e.g., checklists) are 
tools which are not perfect.  They should be used with caution.  It’s a mix of using 
tools, references, with seeing them in action before and after the investment, you 
keep on evaluating them and see how they perform. 
Participant GH04 attended monthly meetings with different subject matter experts who 
updated him on market trends and other implications.  VCs fine tune their “gut feel” or 
intuition with every subsequent deal.  Over time, Participant MN07 became “Finely 
attuned to feeling any semblance of resistance and friction.”  The VCs learned to ask the 
right questions, see beyond façades, remained fiercely curious, and emotionally balanced.  
Participant CD02 reflected, “We look for truth seekers.  There are biases for founders to 
want to move mountains, traverse valleys to prove their thesis is correct.  Are founders 
directed towards traversing the optimal path to uncover the validity of their 
assumptions?”  As the participants assessed more LS management teams in different 
market conditions and several therapeutic areas, they were better equipped to add value to 
the portfolio firm.   Participant MN07 articulated: 
I spend most of my time on the phone inquiring about people, projects, 
technology, and everything.  I’m always, we’re always, thinking about that.  
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There is the investment phase, but there is also the value creation phase.  And you 
always need to be super aware of what is happening in the marketplace.  
 Scholars have previously demonstrated heterogeneity in levels of VC expertise.  
For instance, Clingingsmith and Shane (2017) explained that experienced VCs and 
inexperienced VCs evaluated entrepreneur pitches differently.  Ewens and Rhodes-Kropf 
(2015) asserted that a successful VCs performance is persistent over time, independent of 
the VC firm.  From an opposing perspective, Braun, Jenkinson, and Stoff (2017) showed 
that underperforming VCs are consistent underperformers.  Therefore, underperforming 
VCs may consider modeling the practices of more successful VCs and course correct.    
The BPM model of continuous process improvement aligns with theme four.  
Cultivating and critiquing one’s drug development expertise requires VCs to have 
awareness of their own expertise and to close knowledge gaps.  VCs must ensure their 
knowledge is both current and predictive of the future.  For instance, as the drug 
development landscape continuously evolves, VCs must learn to “see around corners” 
and predict which therapies will be relevant in the future.  Table 3 illustrates the 
participant responses which supported each theme.  Notably, the responses were only 




Participant Responses Supporting Emergent Themes 
Participant ID 
 
Theme 1 Theme 2 Theme 3 Theme 4 
AB01 X X X X 
CD02 X  X  
EF03 X  X  
GH04 X X X X 
IJ05 X X X X 
KL06 X X X X 
MN07 X X X X 
OP08 X  X X 
QR09 X X X X 
ST10 X X X X 
 
Findings Related to Business Process Management  
The conceptual framework for this study was BPM.  Practitioners build a 
framework for continuous improvement in their organizations.  Specifically, BPM is a 
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management discipline about deliberately, collaboratively, and systematically improving 
business processes to accomplish organizational objectives (Hammer, 2015; Jeston & 
Nelis, 2015).  In BPM, all processes must align with the organization’s strategic goals, 
and practitioners must continuously improve their processes.  The VCs overarching 
objective is to ensure they can enter and exit their investments within the fund’s lifespan 
and deliver overall positive returns to their LP investors.  Therefore, when VCs evaluate 
LS management teams, keeping the exit central to decision making (Theme 1) fits into 
the BPM model.  BPM includes process design, modeling, execution, monitoring, and 
optimization phases in its life cycle.  Collapsing the learning timelines (Theme 2), using 
systematic due diligence processes (Theme 3), and cultivating and critiquing one’s drug 
development expertise (Theme 4) resonates with the BPM model of continuous 
improvement in line with the organization’s objectives. 
Applications to Professional Practice  
Scholars and practitioners continue to search for the panacea to reduce investor 
information asymmetry and to reduce inherent decision-making uncertainty.  In this 
study, I explored strategies several VCs used to improve their evaluations processes for 
LS management teams’ drug development capabilities.  I interviewed ten VCs across the 
United States and Canada who successfully evaluated LS management teams’ drug 
development capabilities.  The findings contain themes distilled from approximately 9 
hours of total interview time, annual reports, and online articles.  The participants 
represented a combined VC investment history of over 100 years and hundreds of 
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millions in investment dollars in LS.  The participants directly evaluated numerous LS 
companies and management teams for investment consideration.  
The study outcome offers strategies that, if implemented, could lead to improved 
evaluation of LS management teams and better investment outcomes in the sector.  
Participant GH04 quipped, “It is inexcusable that we operate with a 10% success rate in 
venture capital.  You have Stanford PhDs and really smart people in this business.  We all 
can do better than that.”  If VC firms (including IVC, CVC, and GVC) and angel 
investing firms consider these findings, investment in LS companies could increase with 
enhanced investor confidence.  These results provide actionable solutions for LPs (e.g., 
pension funds, insurance companies, high net worth individuals), who can inquire about a 
VC’s processes during fundraising and make informed decisions when allocating a 
portion of their portfolio to venture capital.  LPs tend to invest when they perceive the 
VC firm has demonstrated a favorable track record and is trustworthy (Kollmann, 
Kuckertz, & Middelberg, 2014; Kuckertz, Kollmann, Röhm, & Middelberg, 2015).  
Entrepreneurs remain cognizant of the needs of investors and other constituents of their 
business (Batterson & Freeman, 2017).  Consequently, these results may afford LS 
management teams with insights on the challenges VCs encounter and the criteria VCs 
use when making investment decisions.    
Implications for Social Change 
The intent of this study was to identify applicable solutions VCs may use to 
improve their evaluation processes of LS management teams.  The results of this study 
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could affect social change in three main ways.  First, with increased investment, LS 
companies can develop new and innovative treatments to improve the welfare and 
longevity of patients.  Investments from high profile endowment funds serves as a quality 
signal for other LPs and investors.  Bermiss et al. (2015) illustrated how the elite Yale 
University’s endowment fund, an LP, acted as an endorsing beacon for nascent venture 
capital firms and their respective portfolio companies.  Second, pension funds, another 
important LP investor in venture capital, are vital sources of retirement income for 
citizens.  Most pension funds in the United States, Canada, and Europe allocate a fraction 
of their portfolio to riskier alternative investments such as venture capital (Andonov, 
Bauer, & Cremers, 2017; Ramsinghani, 2014).  In Canada, pension plans such as the Old 
Age Security, the Canada and Quebec Pension Plans, and Retirement Pension Plan has 
increasing investment in the alternative asset class as low interest rates persist (Bédard-
Pagé, Demers, Tuer, & Tremblay, 2016; Curtis, Dong, Lightman, & Parbst, 2017).  
Improved investment processes may lead to better returns for pension funds, thus 
enhancing citizens economic well-being during their retirement years.  Third, therapeutic 
advances resulting from VC investment impacts employees in many types of 
organizations such as VC firms, biopharmaceutical companies, hospitals, clinics, 
pharmacies, and distribution companies, consequently creating employment and helping 
communities prosper. 
Recommendations for Action 
The recommendations for action are that venture capital professionals should 
implement the strategies identified in the themes of the study to improve their evaluation 
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processes of LS management teams.  VC firms should document their due diligence 
processes, standardize their processes to minimize intra-firm variability, and routinely 
stress test their assumptions.  Further, VC firms should conduct routine process 
assessments and update their processes to include new lessons learned.  In addition to 
implementing the suggested strategies identified in the themes, VCs should continuously 
enhance their sector-specific knowledge of new technologies and vigilantly monitor 
market trends to remain ahead of the competition. 
LS management teams should consider the criteria and processes VCs follow 
when vetting companies for investment.  I have a few recommendations for LS 
management teams.  First, LS management teams should accept investments from VCs 
where a mutual affinity and respect exists.  Relationships lacking respect may lead to an 
antagonistic work environment, opportunistic behavior, and eventual business failure.  
Second, although LS management teams are high performing experts in their respective 
fields, they should learn to be coachable and team oriented to benefit from the VC’s value 
proposition in the drug development market.  Third, LS management who are 
predominately scientists or clinicians should pursue training in finance and accounting.  I 
suggest, at minimum, for the CEO and chief scientific officer to take introductory 
accounting and finance courses and even executive MBAs.   
I will present the data from this study to the Canadian Venture Capital 
Association and the North American Venture Capital Association.  Venture capital 
associations may use the data from the study to develop best practices for VCs during the 
due diligence process and as training for LS entrepreneurs.  I will also disseminate these 
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findings to other stakeholders such as Canadian accelerators and start-up incubators, LS 
companies, and the study participants.  Finally, my intent is to publish this paper in 
ProQuest.     
Recommendations for Further Research 
Research exists on venture capital decision making under conditions of 
uncertainty, however, to my knowledge, no research on how VCs evaluate management 
teams in LS firms existed until this study.  Exploring the strategies some VC use to 
improve their evaluation of LS management teams’ drug development capabilities led to 
the emergence of several themes that future researchers might expand upon.  First, 
researchers could perform a study on strategies VCs use to improve their evaluation 
processes of LS management teams drug development capabilities in different 
geographical locations such as the United States and Europe.  Second, researchers could 
conduct a similar study in different subpopulations of VCs such as male and female VCs, 
corporate and government VCs, VCs from different geographies, and experienced vs 
amateur VCs.  Third, scholars could replicate this study using an angel investor 
population.     
Opportunities for future quantitative studies exist.  As the present study was an 
inductive, qualitative research study, in future, I recommend a quantitative study on VC 
evaluation process of management teams which would include statistical analysis of 
responses gathered from a robust sample of VCs in several geographies.  Expanding the 
geographical locations may provide a broader understanding of VC evaluation processes 
and lead to a more generalizable dataset.   
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This study has some limitations which include the participants’ gender, 
experience levels, and education.  Only one female VC participated in the study and 
therefore I could not explore preliminary differences between male and female VCs.  The 
VCs experience ranged from 4 to 30 years.  Therefore, total investment sums and number 
of deals were not uniform.  The responses from the more experienced VCs were richer 
and nuanced compared to the VCs with less experience.  Finally, the different VC 
educational backgrounds (e.g., science vs business education) may have impacted the 
responses considering LS is a highly technical and niche sector. 
Reflections 
The DBA doctoral study process emphasized the rewards and challenges social 
science researchers encounter to publish rigorous and scientifically reliable results.  The 
process of planning the study and executing the study seemed diametrically opposing 
tasks at first.  My cold calling recruitment tactic for the VCs, notably an upper echelons 
group, was ill-informed, arduous, and felt like a Sisyphean task.  I learned that as in 
business situations, researchers must learn to effectively manage emotions, draft 
contingency plans, and practice patience.   
Despite a lengthier than anticipated recruitment period, once the interviews 
proceeded, each VC was affable, insightful, and contemplative.  The VCs generosity with 
their time, offering a mean interview time of 48 minutes, was humbling and encouraging. 
I entered the data collection phase with a solid understanding of the drug development 
and the clinical research process.  The VCs discussions about the pressures and 
challenges they encounter to select a capable management team to, in turn, provide strong 
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returns for their limited partner investors, broadened my aperture into their investment 
world.  Weeding out unscrupulous or disingenuous management teams from management 
teams at the vanguard of science is not easy under conditions of information uncertainty 
and time constraints.  Despite their differences, the VC-entrepreneur relationship need 
not be mutually exclusive or zero-sum.  Rather, I believe a synergistic and mutually 
beneficial relationship is possible. 
A skill I cultivated was approaching the data collection and analysis process in a 
tabula rasa state.  In my role as a researcher, I directed hyper vigilant attention to the 
research question and minimized any personal bias or preconceived notions.  I asked the 
interview questions without leading the participants, minimized interrupting the 
participant, and included probing questions to confirm my understanding of the responses 
and to minimize ambiguity.  The member checking process confirmed my interpretation 
of the answers before starting the data analysis process.  Distilling, aggregating, and 
disaggregating salient themes from a large volume of interview text, reports, and press 
releases required a systematic approach. 
I developed a newfound respect for the research process and for researchers after 
conducting this study.  While conducting an exhaustive literature review was invaluable, 
the act of synthesizing and creating novel research towards business practice 
exponentially advanced my understanding of venture capital in life sciences.  Finally, the 
DBA in venture capital finance has reinvigorated my interest in alternative investments, 
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the capital markets, academic writing, the research process, and fundamental analysis of 
companies.    
Conclusion 
Venture capitalists invest in LS companies under conditions of information 
asymmetry and high risk.  If VCs improved their evaluation processes of LS management 
teams’ drug development capabilities, they could potentially invest with more confidence 
and provide their LPs with higher returns.  Because LS companies rely on venture capital 
investment to advance their R&D programs, LS management teams should consider the 
VC commentaries outlined in this study.  Although further research is needed, this study 
fills an important gap for VCs who invest in the LS sector and for other stakeholders such 
as LS management teams and LPs.  Despite considerable research in venture capital 
investment decision making, relatively scant information was previously available about 
how VCs evaluate LS management teams.   
I collected data from interviews with venture capital partners and managing 
directors from firms in the United States and Canada who succeeded in improving their 
evaluation processes of LS management teams’ drug development capabilities, reviewed 
annual reports and press releases for data triangulation.  I intentionally selected the 
Canadian LS industry because of declining investment rates in the past decade.  Member- 
checking and data triangulation enhanced the validity of the research.  The four themes 
that emerged from this study were (a) begin with the exit in mind, (b) collapse learning 
timelines, (c) conduct systematic due diligence, and (d) cultivate and critique one’s drug 
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development expertise.  I compared the themes with the published literature and linked 
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Appendix: Interview Protocol and Questions  
The purpose of the interview protocol is to ensure consistency and quality in the 
interview process across all participants.  
Protocol  
1. Greet and thank participants for agreeing to participate in the interview.  
2. Introduce myself and the research purpose to the participants.  
3. Reiterate the voluntary nature to participate and the flexibility to withdraw at 
any time.  
4. Review privacy protections and re-confirm informed consent with the 
participant.  
5. Remind participant the interview is recorded.  
6. Turn on electronic recording device.  
7. Commence the interview  
8. End the interview and discuss member checking procedures to ensure 
accuracy.  
9. Thank the participants for their engagement.  
10. Turn off electronic recording device.  
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Interview Questions  
The interview questions for this study were based on the conceptual framework 
and the central research question.  
1. How do you determine a LS management teams’ capability for developing a 
drug through to commercialization (e.g., discovery, pre-clinical, clinical research, and 
post marketing)?  
2. Please describe the process your organization uses to assess the drug 
development capabilities of a LS management team.  
3. What (if any) were the key challenges to implementing the process of 
assessing LS management teams?  
4. How did you address the key challenges to implementing the process for 
assessing LS management teams?  
5. How does your organization assess the effectiveness of your process for 
evaluating LS management teams?  
6. How, if at all, has your organization improved the effectiveness of your 
process for evaluating LS management teams?  
7. What other information would you like to share about evaluating LS 
management teams’ capabilities that I did not ask?  
